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ABSTRACT 
Trans-10, cis-12-conjugated linoleic acid (trans-10, cis-12-CLA) has been 
reported to reduce body fat mass but accompanied by increased liver mass. However, the 
cellular and molecular mechanisms have been unknown. Our study investigated the effects 
of trans-10, cis-12-CLA supplementation on hepatic gene expression in growing male mice 
by measuring mRNA abundance of thirty-eight genes encoding important enzymes, 
ligand-dependent nuclear receptors, transcription regulators and transporters in lipid 
metabolism. Feeding growing male mice diets supplemented with 0.3% trans-10, 
cis-12-CLA for 6 weeks significantly increased the expression of hepatic genes involved in 
fatty acid uptake (Cd36), TG synthesis (Acaca, Gpam and Scd), lipid droplet formation 
(Plin2), VLDL assembling/secretion (Mttp and Cideb), ketogenesis and utilization (Hmgcs2 
and Bdh1), fatty acid oxidation (Acox1), glyceroneogenesis (Pck1 and Pdk4). The results 
suggest that the increased liver weight in response to trans-10, cis-12-CLA may be due to 
increased fatty acid uptake, stimulated TG synthesis, enhanced formation of lipid droplets 
as well as insufficiently induced VLDL assembly/secretion mechanism in liver. We 
provided new evidences to advance in the knowledge of the effect of this supplement in a 
relatively low amount on hepatic gene expression in growing male mice. 
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CHAPTER 1 
Introduction 
The World Health Organization (WHO) reports that the global epidemic of 
overweight and obesity – “globesity” – is rapidly becoming a major public health problem 
in many parts of the world (1). Over the past two decades, the incidence of overweight and 
obesity has rapidly increased in industrialized countries and currently affects about 72.3% 
of male and 64.1% of female adults in the U.S. (2). Meanwhile, the most recent National 
Health and Nutrition Examination Survey (NHANES) shows that 16.9% of children ages 
2-19 are obese and 31.7% are overweight (3). Besides, the medical care costs ascribed to 
obesity and associated disorders accounted for around $168 billion (4) in the U.S., thus 
constituting a substantial economic burden. In the course of this alarming epidemic trend, 
so-called functional foods that match both the growing health awareness and need for 
convenience attract much attention (5), such as conjugated linoleic acid (CLA). 
CLA refers to a group of conjugated octadecadienoic acid isomers derived from 
linoleic acid (LA), a fatty acid (FA) that contains 18 carbons and 2 double bonds (6). CLA 
isomers are typically found in the products of ruminant animals, such as meat and milk, 
which arises in their gastrointestinal tract where microbes convert LA into different 
isoforms of CLA through biohydrogenation (7). This process changes the position and 
configuration of the double bonds, resulting in a single bond between one or both of the two 
2 
 
double bonds, i.e., trans-10, cis-12-CLA or cis-9, trans-11-CLA. 
Experiments conducted using pure synthetic trans -10, cis-12-CLA have shown 
that this isomer might have beneficial effects against obesity (8), diabetes (9), 
atherosclerosis (10), and cancer (11). The anti-lipogenic effects of dietary CLA mixtures of 
trans-10, cis-12-CLA and cis-9, trans-11-CLA with a ratio of 1:1, were initially observed in 
several lines of mice, and later work using purified isomer preparations clearly showed that 
trans-10, cis-12-CLA was responsible for delipidation (12-16). Supplementation with 
trans-10, cis-12-CLA decreases body fat mass in many animal studies and some human 
studies (41, 42). Furthermore, some previous reports suggest that dietary supplementation 
with CLA reduces body fat mass in overweight humans without disclosing any adverse 
effects (17, 18), indicating that trans-10, cis-12-CLA may be considered as a weight loss 
agent. Therefore, CLA supplements containing trans-10, cis-12-CLA (e.g., Your Life
®
, 
Natrol
®
 and Nature’s Way®, ClarinolTM, Met-Rx, Dymatize®, EAS®) are readily available in 
Health Food Stores and stores where nutritional supplements are sold. 
However, recent studies revealed unfavorable metabolic effects of trans-10, 
cis-12-CLA associated with increased oxidative stress and elevated inflammatory 
biomarkers (19, 20). They have found that trans-10, cis-12-CLA indeed could considerably 
reduced body fat mass but accompanied by hepatic steatosis (5, 12, 21-25) which is an 
excess accumulation of triacylglycerol (TG) in the liver (26) and caused by an imbalance 
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between lipid availability (from circulating lipid uptake or de novo lipogenesis) and lipid 
disposal (via fatty acid oxidation or TG-rich lipoprotein secretion) (27). As trans-10, 
cis-12-CLA supplementation reduces a amount of adipose tissue, several studies suggest 
that much of the increased liver mass may be explained by accumulation of lipids (28, 29) 
derived from mobilization of delipidated adipose tissue stores (30, 31). 
The hepatic steatotic effect of trans-10, cis-12-CLA has been considered to be 
related to modulate the expressions of genes relevant to energy expenditure, apoptosis, fatty 
acid oxidation, lipolysis, differentiation and lipogenesis (6, 32). A study conducted by 
Clément et al. showed that mice fed a diet enriched in trans-10, cis-12-CLA (0.4% w/w) for 
4 weeks developed lipoatrophy, hyperinsulinemia and fatty liver (33). In this study, they 
investigated the levels of expression of genes encoding transcription factors, lipid-binding 
proteins and enzymes known to play a significant role in lipid metabolism (33). Finally, the 
results suggest that liver steatosis might be triggered by trans-10, cis-12-CLA-induced 
hyperinsulinemia, by inducing both fatty acid uptake and lipogenesis as evidenced by the 
substantial up-regulation of peroxisome proliferator activated receptor γ (Pparγ), Cd36, fatty 
acid binding protein 4 (Fabp4) and sterol regulatory element binding transcription factor 1 
(Srebf1) (33). However, the cellular and molecular mechanisms by which trans-10, 
cis-12-CLA results in hepatic steatosis in mice have been unclear. 
To our knowledge, there are no published studies dealing with the genomic effects 
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of chronic dietary trans-10, cis-12-CLA supplementation on liver of growing animals that 
could serve as models for humans. In our previous study (24), relatively low amount of 
trans-10, cis-12-CLA (0.30%) was used compared to other studies (22, 23, 28, 32, 34-36). 
We observed that dietary trans-10, cis-12-CLA resulted in a linear increase in liver weight 
as well as a reduction in adipose tissue weights in both male and female mice over the 
6-week feeding period, which substantiated some published findings obtained at higher 
amounts of CLA (i.e., 0.5-1% of the diet) (28, 37). The present study utilized growing male 
mice which are more susceptible than females (24) to investigate the effects of trans-10, 
cis-12-CLA on hepatic gene expression. Our hypothesis was that long-term increased liver 
mass in response to trans-10, cis-12-CLA would be associated with greater mRNA 
abundance of lipogenic gene networks (Figure 1.1). Specific objectives were to measure 
mRNA abundance of thirty-eight genes (Table 1.1) encoding proteins required for FA 
uptake, FA oxidation, de novo FA synthesis, lipolysis, lipogenesis, ketogenesis, 
carbohydrate metabolism, inflammation, stress response, growth factor signaling, 
transcriptional regulation of lipogenesis and lipid droplet formation.
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Figure 1.1 Currently known relationships among genes analyzed based on manually curated examination of the published literature within the Ingenuity Pathway Analysis 
(www.igenuity.com) knowledge base. Genes are grouped by the predominant process they play in lipid metabolism. Different shapes denote the type of protein encoded by 
the specific genes, including enzymes, ligand-dependent nuclear receptors, transcription regulators, and transporters. Letters along the edges denote effects on activity (A), 
expression (E), localization (LO), proteolysis (L), RNA binding (RB), protein-DNA binding (PD), and protein-protein binding (PP). Gene names are as in Table 1.1. 
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Table 1.1 Gene symbol, description, location, biological process and overall % mRNA abundance among genes measured 
Gene 
symbol 
Description Localization Biological process
1
 % RNA
2
 
Aacs Acetoacetyl-CoA synthetase Cytoplasm FA metabolism 0.57 
Acaca Acetyl-Coenzyme A carboxylase alpha Cytoplasm FA biosynthesis 0.52 
Acox1 Acyl-Coenzyme A oxidase 1 Cytoplasm, peroxisome, 
mitochondrion 
FA oxidation 6.83 
Angptl3 Angiopoietin-like 3 Extracellular space FA metabolism 1.47 
Angptl4 Angiopoietin-like 4 Extracellular space TG homeostasis 0.06 
Apob Apolipoprotein B ER, microsome Lipoprotein metabolism 9.14 
Atf6 Activating transcription factor 6 Nucleus Transcription regulation 0.02 
Bdh1 3-hydroxybutyrate dehydrogenase 1 Mitochondrion Oxidation-reduction process 3.35 
Cd36 CD36 molecule (thrombospondin receptor) Golgi, cell surface, mitochondrion FA transport 0.00 
Chrebp MLX interacting protein-like Cytoplasm, nucleus Glucose homeostasis, transcription 
regulator activity 
2.83 
Cideb Cell death-inducing DNA fragmentation factor 
alpha subunit-like effector B 
Cytosol Apoptosis 3.46 
Cpt1a Carnitine palmitoyltransferase 1a Mitochondrion, microsome FA metabolism 1.91 
Ddit3 DNA-damage inducible transcript 3 Cytoplasm, nucleus Cell cycle, transcription regulation 0.06 
Dgat1 Diacylglycerol O-acyltransferase 1 ER, membrane TG biosynthesis, VLDL assembly 0.15 
Dgat2 Diacylglycerol O-acyltransferase 2 ER, membrane TG biosynthesis, glycerol metabolism 4.93 
Eif2ak3 Eukaryotic translation initiation factor 2 alpha 
kinase 3 
Cytoplasm, ER Srebp-mediated signaling pathway, 
apoptosis 
0.03 
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Table 1.1 (cont.) 
Gene 
symbol 
Description Localization Biological process
1
 % RNA
2
 
Fgfr2 Fibroblast growth factor receptor 2 Nucleus, cell surface Cell-cell signaling 0.05 
Gck Glucokinase Cytoplasm, mitochondrion, nucleus Carbohydrate phosphorylation 0.82 
Gpam Glycerol-3-phosphate acyltransferase, 
mitochondrial 
Mitochondrion, membrane TG biosynthesis, FA hemeostasis 3.18 
Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2 
Mitochondrion Ketogenesis 13.88 
Hspa1b Heat shock 70kDa protein 1B Cytoplasm, mitochondrion, nucleus DNA repair, anti-spoptosis 0.11 
Insig1 Insulin induced gene 1 Endoplasmic reticulum (ER) Cholesterol biosynthesis, TG 
metabolism 
4.14 
Lipc Lipase, hepatic Cell surface, extracellular space FA metabolism, TG metabolism, LDL 
clearance, HDL remodeling 
3.92 
Mlycd Malonyl-CoA decarboxylase Cytoplasm, mitochondrion, 
peroxisome 
FA biosynthesis & oxidation 0.50 
Mttp Microsomal triglyceride transfer protein Golgi, ER Lipoprotein transport, TG metabolism 1.24 
Pcx Pyruvate carboxylase Mitochondrion Gluconeogenesis, lipid biosynthesis 1.42 
Pck1 Phosphoenolpyruvate carboxykinase 1 Cytoplasm, nucleus Gluconeogenesis, lipid metabolism, 
glycerol biosynthesis 
14.79 
Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4  Mitochondrion Glucose metabolism 0.13 
Plin2 Perilipin 2 Cytoplasm, nucleus, plasma 
membrane 
Lipid storage, long-chain FA transport 1.61 
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1 
Entrez Gene, National Center for Biotechnology Information (NCBI). 
2 
The % mRNA abundance is calculated by [((1/E
ΔCt
) specific gene/sum (1/E
ΔCt
) all genes) x 100]. See Experimental Methods for details 
 
Table 1.1 (cont.) 
Gene 
symbol 
Description Localization Biological process
1
 % RNA
2
 
Pnpla2 Patatin-like phospholipase domain containing 2 Cytosol, membrane Lipid catabolic process 0.33 
Ppara Peroxisome proliferator activated receptor 
alpha 
Nucleus FA metabolism, glucose metabolism, 
transcription  
1.28 
Saa1 Serum amyloid A 1 Extracellular space Cholesterol metabolism 0.54 
Scd Stearoyl-Coenzyme A desaturase 1  ER membrane FA biosynthesis 2.53 
Slc27a2 Solute carrier family 27 member 2 ER, microsome, peroxisome FA transport, lipid metabolism 3.63 
Slc2a1 Solute carrier family 2 member 1 Cytoplasm, plasma membrane Glucose transport 0.07 
Srebf1 Sterol regulatory element binding factor 1 Golgi, ER, nucleus Transcription regulation 0.67 
Ucp2 Uncoupling protein 2 Membrane, mitochondrion Mitochondrion transport, response to 
superoxide 
0.19 
Xbp1 X-box binding protein 1 Nucleus Transcription 9.67 
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CHAPTER 2 
Literature review 
Currently, more than two-thirds of American adults and nearly one-third of 
children and teens are either overweight or obese (2). Since 1980, the number of obese 
adults has doubled (38). Since 1970, the number of obese children ages 6-11 has quadrupled, 
and the number of obese adolescents ages 12-19 has tripled (38, 39). Obesity-related 
medical costs are nearly 10 percent of all annual medical spending (40). The alarming 
increases in obesity rates over the past two decades has attracted much attention to the 
anti-lipogenic effects of the trans-10, cis-12-CLA. Supplementation with trans-10, 
cis-12-CLA has been reported to reduce body fat mass in many animal studies and some 
human studies (41, 42). Besides, CLA supplements containing trans-10, cis-12-CLA are 
readily available in Health Food Stores and stores where nutritional supplements are sold.  
Although trans-10, cis-12-CLA seems to be a promising substance as regards reduction of 
body fat, it is important to consider the possibility of adverse effects found in animal models 
(43, 44) and more recently in specific groups of humans (45-47). The most recent studies 
have stated that trans-10, cis-12-CLA could cause hepatic steatosis in mice (5, 12, 21-25, 
33). However, fatty liver formation due to trans-10, cis-12-CLA has not been reported in 
human as seen in mice. As CLA has been approved by FDA in GRAS category, considering 
the possible adverse effects of long-term use of CLA, especially trans-10, cis-12-CLA 
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isomer, further and more studies in animals and humans are urgently needed before the 
trans-10, cis-12-CLA usages as a dietary supplement to reduce obesity in humans (48). 
This chapter will begin with the introduction of CLA, focusing on trans-10, cis-12-CLA 
isomer. Then it will discuss the physiological effects of trans-10, cis-12-CLA on adipose 
tissue and liver by reviewing in vitro, in vivo and clinical studies. Finally, it will summarize 
proposed underlying mechanisms through which trans-10, cis-12-CLA isomer exhibits its 
hepatic steatotic effect. 
 
Definition of trans-10, cis-12-CLA 
     CLA is a fatty acid belonging to the group of polyunsaturated fatty acids (PUFAs) 
(49) as well as a generic term for the geometric and positional isomers of LA (cis-9, cis-12, 
octadecadienoic acid) (50) which contains 18 carbons and 2 double bonds. But, there is no 
methylene group separating the double bonds of CLA as there is in LA (51). Instead, the 
two double bonds are separated by one single bond (51) and are present predominantly in 
positions of carbons 9 and 11 (cis-9, trans-11-CLA), and 10 and 12 (trans-10, cis-12-CLA), 
which are two most studied CLA isomers (Figure 2.1). 
CLA is formed in the gastrointestinal tract of ruminant animals where microbes 
convert LA into different isoforms of CLA through incomplete biohydrogenation (49), 
resulting in a single bond between one or both of the two double bonds (52). But, it has 
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been demonstrated that CLA can be also endogenously synthesized from vaccenic acid by 
Δ9-desaturase in rumens of lactating cows (53) and in lactating women (54). Therefore, 
natural forms of CLA can be found predominantly in ruminant food products, such as milk, 
cheese and beef (55-57), and present primarily (90%) as cis-9, trans-11-CLA (52, 53). 
According to Atkinson, the amount of CLA obtained by foods is 200 mg/day (58); Chin et 
al. estimated that the daily intake of CLA in humans is approximately 160 mg (59) and 
Ritzenthaler et al. suggested 212 mg in men and 151 mg in women (60). Hence, in order to 
obtain the beneficial effects of CLA on health, it is necessary to include an additional 
supplementation of CLA in the habitual diet in view of the amount and type of isomer 
consumed habitually (49). 
        Commercial preparations of CLA supplements are synthesized by alkaline 
isomerization of LA-enriched vegetable oils (e.g. safflower and sunflower oil) (61). This 
type of processing yields a CLA mixture containing approximately 40% of the cis-9, 
trans-11-CLA isomer and 44% of the trans-10, cis-12-CLA isomer (16). Commercial 
preparations also include about 4-10% trans-9, trans-11-CLA and trans-10, trans-12-CLA 
as well as trace amounts of other isomers (52). In 1997, only two companies (Natural ASA, 
Hovdebygda, Norway; PharmaNutrients Inc., Lake Bluff, IL) marketed CLA as a dietary 
supplement (62). Today numerous companies offer dietary supplements containing CLA; 
examples include Your Life®, Natrol® and Nature’s Way® (63), ClarinolTM, Met-Rx, 
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Dymatize® and EAS®, claiming a variety of health benefits. Supplement manufacturers 
recommend doses of 3-3.4 g per day for weight loss purpose (Clarinol, Tonalin) (64). 
 
Physiological effects of trans-10, cis-12-CLA 
CLA was discovered quite accidentally by Pariza and hargraves when they were 
investigating the carcinogenic properties of grilled beef; and they surprisingly and 
unexpectedly found that the fatty acids present in grilled beef exhibited anticarcinogenic 
rather than procarcinogenic properties (65). Ever since then, a large number of studies have 
been done using a 1:1 ratio of cis-9, trans-11-CLA and trans-10, cis-12-CLA both in vivo 
and in vitro (16), aiming to investigate CLA’s several beneficial effects in health-related 
disorders. The results have shown that CLAs have anti-adipogenic (12, 13, 16), 
anti-carcinogenic (56, 66-72), anti-atherogenic (73-76), anti-diabetogenic (77, 78) and 
anti-inflammatory (79-82) properties. Among all the CLA isomers, the cis-9, trans-11-CLA 
and trans-10, cis-12-CLA isomers have various physiological functions and exhibit health 
benefits, individually or in association with each other (83, 84). Park et al. were the first to 
demonstrate that CLA mixture of 50% cis-9, trans-11-CLA and 50% trans-10, cis-12-CLA 
modulated body composition by decreasing body fat mass and increasing lean body mass 
(13). Experiments conducted later have confirmed that trans-10, cis-12-CLA is the isomer 
responsible for the changes in vivo and in vitro, particularly in body composition and lipid 
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metabolism (12, 14-16, 33, 85). 
 
Trans-10, cis-12-CLA’s effect on adipose tissue 
In vitro studies 
     Brown and Mclnstosh found that trans-10, cis-12-CLA attenuated TG content and 
differentiation in primary cultures of human adipocyte (86). Similarly, a study demonstrated 
that trans-10, cis-12-CLA treatment at doses to those found in serum from rodents reduced 
adipogenesis and lipid droplet accumulation (87). In a study conducted by Park et al., 
trans-10, cis-12-CLA reduced TG content in the 3T3-L1 adipocytes (88). 
 
In vivo studies 
Dietary trans-10, cis-12-CLA supplementation has been demonstrated to be 
extremely effective at reducing the fat content (≥ 60%) in a number of rodent models and 
pigs (89). Navarro et al. investigated the effect of 6 weeks of supplementation of 0.5% 
linoleic acid, cis-9, trans-11-CLA or trans-10, cis-12-CLA in atherogenic diet-fed hamsters. 
Although there was no difference in body weight, fat mass decreased significantly in 
trans-10, cis-12-CLA-fed hamsters (90). Another study showed that intake of trans-10, 
cis-12-CLA isomer for 3 weeks in genetically obese mice decreased gain in body weight 
and white fat pad weight (91). In a study conducted by Kang et al. using wild-type and 
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stearoyl-CoA desturase 1 (Scd1) null mice, trans-10, cis-12-CLA decreased fat mass and 
enhanced mRNA expression of lipogenic enzymes, fatty acid synthase (Fasn) and 
uncoupling protein 2 (Ucp2), suggesting that antiobesity effects of trans-10, cis-12-CLA is 
independent of Scd1 gene expression and enzyme activity (92). House et al. conducted a 
study using a polygenic obese line of mice fed 1% trans-10, cis-12-CLA and showed that 
adipose mass was 30% less in the epididymal depot of CLA-fed mice, 27% less in the 
mesenteric depot and 58% less in brown adipose tissue after 14 days of CLA treatment (28). 
In contrast, a study in adult male Wistar rats fed with diets containing 1% trans-10, 
cis-12-CLA in combination with moderate physical activity for 6 weeks did not observe any 
effect on body composition or body weight (93). Based on the studies above, it is suggested 
that adult animals have not reproduced the dramatic results seen in growing animals (51). 
Additionally, mice are more sensitive to CLA than rats in loosing fat mass (51), as Kim et al. 
stated that CLA-induced reductions in body fat gain varied in different species as following: 
mice > hamster > rats (94). 
Some of the mechanisms suggested to be involved in fat reduction with trans-10, 
cis-12-CLA intake are increased energy expenditure (95), increased fat oxidation (96), 
decreased adipocyte size (97), and inhibition of enzymes involved in fatty acid metabolism 
and lipogenesis (83, 98, 99). 
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Clinical studies 
        Although the body fat-lowering effect of trans-10, cis-12-CLA has also been 
reported in humans, most clinical studies have not reflected the dramatic findings obtained 
in vitro and in vivo studies (51). In a controlled, randomized, double-blind parallel group 
study, the participants were given 2.2-4.2 g/d of trans-10, cis-12-CLA, or cis-9, 
trans-11-CLA, or combined for 4-12 wk (100). The results showed a certain reduction of 
the proportion of body fat especially abdominal fat by trans-10, cis-12-CLA (100). It should 
be noted that the loss of body fat is 40-50% greater in mice than observed in humans (61); 
however, mice are generally fed approximately 5 times more CLA than humans (per 
kilogram body weight) (101). In another randomized, double-blind controlled trial, 60 
abdominally obese men were treated with 3.4 g/day CLA mixture, purified trans-10, 
cis-12-CLA or placebo for 12 weeks (46). The study found that trans-10, cis-12-CLA 
decreased body fat, sagittal abdominal diameter and weight versus baseline, but the 
difference was not significantly different from placebo; besides, the CLA mixture did not 
change body composition or weight compared with placebo (46).  
Malpuech-Brugere et al. examined the effects of cis-9, trans-10-CLA and 
trans-10, cis-12-CLA isomers at two different intakes on body composition in 81 
middle-aged overweight healthy humans (102). This was a bicentric, placebo-controlled, 
double-blind, randomized study. After 6-week consuming daily a dairy product containing 3 
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g of high oleic acid sunflower oil, volunteers were randomized to receive daily either 3 g of 
high oleic acid sunflower oil, 1.5 g of cis-9, trans-11-CLA, 3 g of cis-9, trans-11-CLA, 1.5 
g of trans-10, cis-12-CLA, or 3 g of trans-10, cis-12-CLA administrated as TG in a dairy 
product for 18 weeks. At the end of the 24 weeks, they did not find any significant 
differences in body composition and energetic uptake among the groups. Similarly, a study 
investigating the effects of 3 doses of highly enriched cis-9, trans-11 or trans-10, 
cis-12-CLA in healthy men did not demonstrate any significant alteration caused by any of 
those two isomers in the body composition of healthy adults (103). 
In the vast majority of the studies with human volunteers, CLA mixtures rather 
than pure isomers have been used for supplementation (104). The effectiveness of CLA on 
humans is controversial. This may be partly because CLA dosage used in human studies is 
much lower than doses used in animal studies (51). For example, subjects in the human 
study received approximately 0.05 g/kg body weight CLA (105), the mice received 1.07 
g/kg body weight CLA (106), which was 20 times the human dose based on body weight. 
Moreover, most animal studies have been in growing mice or rats, whereas studies in 
humans were mostly in mature volunteers whose changes in body composition in response 
to CLA supplementation have not been as dramatic as those seen in young animals (51). 
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Trans-10, cis-12-CLA’s effect on liver 
Although CLA seems to be a promising substance as regards reduction of body fat, 
it is important to consider the possibility of adverse effects found in animal models and 
more recently in specific groups of humans (49). Liver has been reported to be an important 
target for the effects of CLA on lipid metabolism (36). Many recent studies revealed that 
CLA could considerably reduced body fat mass but accompanied by hepatic steatosis (5, 12, 
21-25). They also verified that trans-10, cis-12-CLA is the isomer responsible for the 
presence of fatty liver in mice associated with the loss of adipose tissue (12, 25, 31, 33, 107).     
The studies discussed in this section were summarized in Table A.5-A.7. 
 
In vitro studies 
        A study conducted by Eder et al. showed that treating HepG2 cells with trans-10, 
cis-12-CLA increases the concentration of saturated fatty acid (SFA) in various cell lipid 
fractions at the expense of monounsaturated fatty acid (MUFA) (108), which confirms the 
investigation conducted by Choi et al. that clearly demonstrated that trans-10, cis-12-CLA 
strongly suppresses Δ9-desaturase (109). Choi et al. found that treating HepG2 cells with 
trans-10, cis-12-CLA did not cause changes in the Scd gene transcription, mRNA and 
protein levels; however, this isomer decreased both the Scd activity as well as the levels of 
MUFAs, suggesting that in HepG2 cells the it regulates human Scd activity mainly by a 
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posttranslational mechanism (109). Since data from Belury and Kempa-Stedzko (110) 
suggested that liver microsomes may desaturate linoleate as well as CLA, Bretillon et al. 
(111) utilized male Wistar rat liver microsomes to investigate the effects of trans-10, 
cis-12-CLA on the desaturation of C18 fatty acids. They found that trans-10, cis-12-CLA 
significantly inhibited the conversion of stearic acid and the Δ6 desaturation of LA at the 
highest inhibitor/substrate (I/S) ratio. Another study demonstrated significant cytotoxic 
effects of 1 μM trans-10, cis-12-CLA on dRLh-84 rat hepatoma cells (50). 
 
In vivo studies 
        Studies in trans-10, cis-12-CLA supplementation have shown inconsistent results 
when comparing its effects on liver metabolism in different animal species. Thus, as 
Moya-Camarena and Belury suggested, there was the existence of a species-specific 
response of liver to CLA (and trans-10, cis-12-CLA) feeding (112). 
Numerous studies have shown that feeding trans-10, cis-12-CLA leads to an 
increase in liver weight in mice. As mentioned previously, the study observing a reduction 
in adipose tissue in response to 1% trans-10, cis-12-CLA supplementation for 14 days, 
found that livers of the CLA-fed mice accumulated more fat and mass than the livers from 
LA-fed mice (control group) (32). Clément et al. showed that C57B1/6J female mice fed a 
diet enriched in trans-10, cis-12-CLA (0.4% w/w) for 4 weeks resulted in a dramatic 
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decrease in the mass of peri-uteral white adipose tissue (WAT) but accompanied by 
triggering a massive enlargement of the liver (3.1-fold increase) with typical features of a 
fatty liver: pale color and accumulation of intracellular lipids (33). They also suggest that 
trans-10, cis-12-CLA-induced hyperinsulinemia may trigger liver steatosis by inducing both 
fatty acid uptake and lipogenesis (33). Another group using aging female C57B1/6J mice 
pointed out that feeding 0.5% trans-10, cis-12-CLA for 6 months reduced the fat mass and 
induced liver hypertrophy accompanied by the accumulation of lipids in liver (48) . In a 
study conducted by Degrace et al., C57BL/6j male mice were randomized to receive either 
10g of oleic acid, cis-9, trans-11-CLA, or trans-10, cis-12-CLA for 4 weeks (30). The study 
observed a marked regression of the perieididymal adipose tissue (PAT) and a concomitant 
enlargement of liver associated with a sever fat accumulation (30). Their follow-up study 
confirmed their previous findings and found that the livers of trans-10, cis-12-CLA-fed 
mice had 170 μmol more TG and 1.1 μmol more total protein compared to those of controls 
(31). Due to the increased fatty acid oxidation capacities, they also suggested that hepatic 
steatosis was not caused by impaired fatty acid oxidation in C57BL/6J mice fed the trans-10, 
cis-12-CLA (31). A study using eighteen C57BL/6N female mice fed with either a control 
diet or diets supplemented with 0.5% cis-9, trans-11-CLA or 0.5% trans-10, cis-12-CLA for 
8 weeks, found that the weights of the livers in the mice fed trans-10, cis-12-CLA was 
significantly (p < 0.05) greater than those in the control and cis-9, trans-11-CLA groups; 
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similarly, the weight of total liver lipids was approximately 4 times greater in the trans-10, 
cis-12-CLA than other groups, which was mainly due to an increase (5-fold) in the TG 
fractions, but cholesterol (3-fold), cholesterol esters (3-fold), and free fatty acids (2-fold) 
were also significantly increased (25). House et al. measured gene expression during 
trans-10, cis-12-CLA-induced fat reduction in polygenic obese line of mice. They observed 
an 33% increase (p < 0.0001) in liver weight by day 14 with 61% more fat present in the 
liver of trans-10, cis-12-CLA-fed mice compared with LA-fed mice (p < 0.001) (28). 
Similarly, Warren et al. also found that livers from the mice fed trans-10, cis-12-CLA 
contained 5 times more lipids than in the control group, with 30% lipids of the liver wet 
weights compared with 12% lipids of the liver wet weights in the control group (113). 
According to the studies (25, 30, 32, 33) that also measured the hepatic TG content, hepatic 
enlargement was associated with a 3- to 7-fold increase in TG content. Furthermore, our 
previous study suggested the lower threshold for these hepatic responses may be 0.15% 
trans-10, cis-12-CLA or less in a diet (24). 
        Several studies in hamsters have demonstrated different effects of trans-10, 
cis-12-CLA on liver compared with other rodent species, such as the mouse and the rat 
(114). Zabala et al. also observed a significantly greater liver weight (p < 0.05) produced by 
5 g trans-10, cis-12-CLA, but with significantly lower TG content (p < 0.01) in 9-week-old 
male hamsters, indicating that the increased liver weight was not due to increased fat 
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accumulation (114). Moreover, they pointed out that the liver TG content in those mice was 
even significantly lower than that in the linoleic acid group; and, that reduced fat deposition 
in liver was not apparently due to changes in lipogenesis and should be ascribed to an 
increase in fatty acids oxidation (114). Another group showed that feeding male F1B hybrid 
hamsters with trans-10, cis-12-CLA (6.6 g/kg diet) for 8 weeks reduced weight gain as well 
as increased liver weight by 25% but not liver lipids (85). 
In the study conducted by Gudbrandsen et al., feeding male Zucker fa/fa rats diets 
supplemented with 1% trans-10, cis-12-CLA for 10 days reduced the liver TG content 
without improving the overall adiposity or any change in liver weight (36). On contrary, 
another study observed a 33% increase in liver lipid content in the growing female Zucker 
fa/fa rats fed trans-10, cis-12-CLA (1.5 g CLA/kg BW) for 21 days (89). 
 
Clinical studies 
        So far CLA supplement on the market has been a mixture of trans-10, cis-12-CLA 
and cis-9, trans-11-CLA at an equal proportion and supplement manufacturers recommend 
doses of 3-3.4 g per day for weight loss purpose (Clarinol, Tonalin) (64). Most clinical trials 
studying the safety of CLA in humans typically lasted between 4 and 13 weeks and dosages 
were 1.4-4.2 g, with a few exceptions that employed 6-6.8 g (115). A very recent study (64) 
determining the safety of a very high-dose (14.6 g cis-9, trans-11-CLA and 4.7 g trans-10, 
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cis-12-CLA per day) of CLA which was almost 3 times higher than the highest dose in 
previous studies on CLA (115), did not found any clinically relevant effects on liver 
function tests of the 19 participants after taking CLA supplement for 3 weeks. Thus, it 
ended up with the conclusion that doses of up to 3 g per day as commonly ingested from 
CLA supplements are unlikely to affect liver function at least over a period of weeks (64). 
However, the results of this study did not suggest that trans-10, cis-12-CLA would not 
cause any liver damage in such high dose. First, the content of trans-10, cis-12-CLA in CLA 
mixture they used was much lower than the other isomer. Because these two CLA isomers 
are responsible for different biological functions, so the high cis-9, trans-11-CLA content 
might affect or mask the influence of trans-10, cis-12-CLA on liver. Second, the subjects 
were mostly young women and only 19 participants were involved in this study; thereby, 
they were not very representative. Finally, the study only measured several biomarkers of 
liver function and those measurements could not indicate any change in liver weight. 
        A randomized, crossover, single-blind clinical trial (116) was carried out by 
Venkatramanan et al. in 11 moderately overweight, borderline hyperlipidemic individuals 
who consumed milk enriched with a 4.2% synthetic mixture of trans-10, cis-12-CLA and 
cis-9, trans-11-CLA isomers providing 1.3 g/d of CLA. The results indicated that 
supplementation with CLA-enriched milk did not significantly affect liver function or body 
weight (116). Since trans-10, cis-12-CLA is responsible for reducing fat mass and 
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increasing liver weight, the relatively low amount of this isomer used in the study may be at 
a level below the threshold necessary to elicit changes in body composition (116). However, 
this study utilized CLA in a food format with milk, which could possibly enhance the 
absorption and metabolism of the CLA supplement compared with those in a purified 
compound format. Similarly, neither Berven et al. (117) nor Blankson et al. (45) reported 
any clinically important changes in the blood levels of liver enzymes during the 12-week 
treatment with a mixture of trans-10, cis-12-CLA and cis-9, trans-11-CLA at an equal 
proportion. Lowery et al. also found no effect of the CLA mixture on the liver enzyme 
transferases in novice body builders supplemented with a two-isomer preparation (3.9 g/d) 
for 6 weeks (118). 
        In a study (119) trying to determine the safety of CLA in Japanese, 60 healthy 
overweight male were randomly assigned to three groups: 5.4 g CLA-triacyglycerol (3.4 g 
CLA), 10.8 g CLA- triacyglycerol (6.8 g CLA) and placebo daily for 12 weeks. The CLA- 
triacyglycerol contained trans-10, cis-12-CLA and cis-9, trans-11-CLA at an equal 
proportion (119). The study observed a slight increase in the level of liver enzymes (serum 
AST and ALT activities) in the 6.8 CLA group at 12 weeks; however, these changes were 
within the normal range (119). The results also indicate that CLA at a dose of 3.4 g/d is a 
safe dietary level in healthy Japanese populations based on no clinically significant changes 
in vital signs. 
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        The long-term safety of CLA supplement was evaluated by a randomized, 
double-blind study consisting of 50 obese humans for one-year period (120). Subjects were 
randomized to receive either 6 g/day of CLA mixed isomers (as 7.5 g/day ClarinolTM) 
containing 37.3% cis-9, trans-11-CLA and 37.6% trans-10, cis-12-CLA, or placebo (high 
oleic sunflower oil) (120). The results showed that body composition did not differ between 
groups and liver function was not affected, in terms of ALT, AST and alkaline phosphatase 
in serum (120). The study concluded that CLA as ClarinolTM is safe for use in obese 
humans for at least one year (120). 
        So far there have been no clinical studies investigating the effects or safety of 
trans-10, cis-12-CLA supplementation by utilizing the purified isomer. Hence, we can get 
few hints from those studies using mixed isomers which may negate one another. Moreover, 
doses used in human trials were much lower than those used in animal studies (86). 
Therefore, in future, a large number of studies using different amounts of purified trans-10, 
cis-12-CLA supplement need to be carried out to investigate its effect on liver weight in 
humans. Furthermore, those studies need to be duplicated in other labs giving emphasis to 
men and women, age groups, ethnic background or food style (121). All in all, trans-10, 
cis-12-CLA-specific dose-titrated world-wide network clinical trials combined with 
mechanistic studies in cultures of primary cells should provide the much needed insight on 
potential human applications for this isomer (121). When extrapolating rodent data, such as 
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mouse, rat and hamster, to the human situation, the differences in species’ sensitivities are of 
great importance (122, 123).  
 
Hypothesized working mechanisms of trans-10, cis-12-CLA in liver 
Increased hepatic lipogenesis 
It was suggested that fatty liver could be a consequence of the increased 
lipogenesis in the liver in compensating for the reduction of fat deposition in the adipose 
tissue (124-126). A study found that increased fatty acid synthesis seemed to contribute to 
the trans-10, cis-12-CLA-induced fatty liver, evidenced by the increased expression of four 
lipogenic genes by more than 2-fold, including acetyl-CoA carboxylase (Acaca), fatty acid 
synthase (Fasn), malic enzyme (Me) and stearoyl CoA desaturase-1 (Scd1) (127). Indeed, 
the strong and specific induction of genes expressed at only very low levels in the normal 
liver, such as those encoding PPARγ, Fat/Cd36, and Albp, was observed in mice fed the 
trans-10, cis-12-CLA (33).These modifications may be accounted for by the concomitant 
induction of Srebf1 gene (33), which is known to be a major regulator of hepatic lipogenic 
program (128). Jaudszus et al. in a very recent study speculated that the reduction in the 
white adipose tissue in the trans-10, cis-12-CLA group was likely compensated by the 
hepatomegaly due to redistribution, altered oxidation and/or increased de novo synthesis of 
fatty acids (5). Therefore, the profound hepatic steatosis showed by animals consuming 
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trans-10, cis-12-CLA isomer has been attributed to increased hepatic TG, cholesterol, 
cholesterol esters and free fatty acids (FFAs) (25), reflecting increased hepatic fatty acids 
synthesis (124). These observations strongly indicated that an increase in lipogenesis is 
primarily responsible for the trans-10, cis-12-CLA-dependent accumulation of TG in the 
liver (129). 
On contrary, a study (114) assessing the effects of trans-10, cis-12-CLA on 
mRNA levels and the activities of several lipogenic enzymes in hamsters, demonstrated that 
trans-10, cis-12-CLA isomer produced significantly greater liver weight but also 
significantly decreased liver fat accumulation. The study also observed no changes in 
mRNA levels or the activities of lipogenic enzymes (114). In terms of HepG2 cells, 
treatment of trans-10, cis-12-CLA did not cause changes in the Scd gene transcription, 
mRNA and protein levels (109). 
 
Direct activation of PPARs 
        It was suggested that the observed trans-10, cis-12-CLA-mediated increased liver 
weight result from the direct activation of peroxisome proliferator-activated receptors 
(PPARs) (121, 130) and subsequent “switching on and/or off” of the target genes to elicit a 
host of biochemical pathways (131). According to the proposed CLA-mediated signal 
transduction by Benjamin et al. in Figure 2.2, during gene regulation, the well characterized 
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PPARs (α, β or γ subtypes) bind to the peroxisome proliferator responsive element (PPRE) 
on the nuclear DNA as heterodimers with the α, β or γ subtypes of the retinoic acid receptor 
(RXR), which in turn, needs to be activated by cis-9-retinoic acid to effect target gene 
transcription (132, 133). 
        As trans-10, cis-12-CLA has been reported to be a potent ligand for Pparα (134), 
the underlying regulations might imply the activation of Pparα, which was shown to repress 
apoptosis (135) and therefore to favor liver enlargement. Rasooly et al. observed a 65% 
reduction in Pparα gene expression in the liver of the mice fed trans-10, cis-12-CLA diet 
(127). The down-regulation of Pparα in the liver seems to be pivotal for the hepatic 
abnormalities (113). LaRosa et al. pointed out that suppression of Pparα is considered to be 
an integrated response to cellular stress, e.g. due to lipid peroxidation, leading to the 
activation of the nuclear factor of kappa light polypeptide gene enhancer in B-cells (NFκB) 
(136). Furthermore, down-regulation of Pparα as a central regulator of lipid homeostasis 
determines the inhibition of β oxidation and results, for example, in an over-expression of 
Srebf1 in the liver (137). Srebf1 controls a multitude of genes involved in hepatic de novo 
lipogenesis, such as Dgat (30) and Scd (5). See Figure 2.3. 
 
Indirect mechanism: hyperinsulinemia 
        Several lines of evidence strongly suggest that the liver steatosis occurring in 
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trans-10, cis-12-CLA-fed mice is secondary to hyperinsulinemia, which causes high levels 
of fatty acid uptake and synthesis (33). First, because white adipose tissue plays a crucial 
role in metabolizing and converting glucose to fatty acid for storage purposes, the large 
decrease of fat pad mass in response to dietary trans-10, cis-12-CLA may result in a 
retardation of whole-body glucose metabolism (129). Therefore, Ide et al. speculated that 
there is a possibility that the counteraction of trans-10, cis-12-CLA-mediated induction of 
hepatic lipogenesis aggravates glucose intolerance and hyperinsulinemia, despite being 
potentially effective in preventing fatty liver (129). A large increase in lipogenesis and 
accumulation of TG in the liver after trans-10, cis-12-CLA treatment may represent the 
physiological response of the animal to metabolize excess glucose to fatty acid and store it 
as TG in the liver rather than in adipose tissue (129). Second, Clément et al. pointed out that 
fatty liver was not observed in cis-9, trans-11-CLA-fed mice, which remained 
normoinsulinemic (33). Third, hyperinsulinemia is associated with the induction of Pparγ 
gene expression in the liver and with liver steatosis in several mouse models (126). Fourth, 
insulin is known to upregulate Pparγ gene expression in adipocytes (138) and to induce Fas 
gene expression in the liver (139, 140). Finally, Clément et al. also demonstrated 
down-regulation of Pck1, strongly suggesting that the livers of trans-10, cis-12-CLA-fed 
mice remain sensitive to insulin (33). 
Several in vivo studies have reported that dietary CLA caused marked glucose 
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intolerance and hyperinsulinemia (33, 141). Clément et al. showed that the mice fed a diet 
enriched in trans-10, cis-12-CLA (0.4% w/w) for 4 weeks developed lipoatrophy, 
hyperinsulinemia and fatty liver (33). In their study, a dramatic increase in non fasting 
plasma insulin levels was observed in mice fed the trans-10, cis-12-CLA-enriched diet, 
these mice displaying insulin concentrations 10 times higher than mice fed control and LA- 
or cis-9, trans-11-CLA-enriched diets; and, despite this marked hyperinsulinemia, plasma 
glucose concentration remained within the normal range in these mice (33). Another study 
found that trans-10, cis-12-CLA diet promoted insulin resistance and increased serum 
glucose (p = 0.025) and insulin (p = 0.01) concentrations in ob/ob C57BL-6 mice (141). 
Risérus et al. (142) conducted a clinical study including 57 non-diabetic abdominally obese 
men to randomly receive either 3.4 g trans-10, cis-12-CLA or control oil. After 12-week 
treatment, they demonstrated that trans-10, cis-12-CLA induced hyperproinsulinaemia that 
was related to impaired insulin sensitivity, independently of changes in insulin 
concentrations in obese men (142). Thus, they suspected the use of weight-loss supplements 
containing this CLA isomer (142). 
However, the cause of the dramatic hyperinsulinemia triggered by the trans-10, 
cis-12-CLA remains to be determined. 
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Insufficient hepatic VLDL secretion in liver 
        In general, TG which is formed by esterification of fatty acid derived from plasma, 
is stored as droplets or secreted in the form of VLDL whose secretion depends on the 
synthesis of TG as well as apoB-containing lipoproteins which are major lipoproteins in 
transporting the hepatic lipids out of the liver (143). Thus, an alteration of VLDL secretion 
rates could also result in liver fat accumulation (30). 
        A study (144) aimed to investigate the effects of trans-10, cis-12-CLA on liver 
lipid metabolism in cultured HepG2 cells, which are human hepatoma cells and are known 
to exert a number of human liver functions, including fatty acid uptake, lipid synthesis, 
VLDL assembly and VLDL secretion (145). A novel finding in this study is that this CLA 
isomer suppressed TG secretion in spite of the fact that it increased 4-fold the cellular TG 
content (144). Since the secreted TG is mainly contained in VLDL, the decreased TG 
secretion by trans-10, cis-12-CLA reflects a diminished secretion of VLDL (144). 
Yotsumoto et al. found that apoB secretion by HepG2 cells treated with 10 μM trans-10, 
cis-12-CLA for 24 hours was decreased markedly when compared with the control group; 
and this CLA isomer also inhibited cellular TG and cholesteryl ester synthesis (146). Thus, 
this study suggests that trans-10, cis-12-CLA inhibited TG synthesis and reduced apoB 
secretion (146). 
        In terms of in vivo studies, Degrace et al. (30) demonstrated that the steatosis 
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accompanying the fat loss induced by trans-10, cis-12-CLA in C57BL/6j mice was not due 
to an alteration of the liver lipoprotein production that was even increased. The data 
obtained in that study showed that the ability of the total liver to secrete VLDL was 
practically two times greater in trans-10, cis-12-CLA-fed mice than in controls (30). 
Therefore, they indicated that the liver TG accumulation could not be attributed to a 
decreased VLDL secretion and that the VLDL overproduction from the enlarged liver was 
however insufficient to eliminate the flux of fatty acid entering the whole esterification and 
lipoprotein assembling/secretion pathway (30). According to the different results between 
HepG2 cells and mice, the explanations regarding the relations between the setup of the 
liver steatosis and VLDL secretion in mice fed diets containing purified trans-10, 
cis-12-CLA are very scarce and still confused. 
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Figure 2.1 Structure of LA and its major CLA derivatives. 1. LA; 2. cis-9, trans-11-CLA; 3. 
trans-10, cis-12-CLA (121). 
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Figure 2.2 Proposed CLA-mediated signal transduction. The dietary lipid nutrient L (L = 
here CLA) crossing the cell membrane with the help of specific membrane-bound fatty acid 
transporters and binds to tissue-specific fatty acid binding protein (FABP) in the cytosol; 2. 
The L/FABP complex enters the nucleoplasm, where L is transferred to the specific 
peroxisome proliferators activated receptor (PPAR) subtype; 3. The L/PPAR complex 
heterodimerises with retinoic acid (RA)/retinoic acid receptor (RXR) subtype; 4. This 
heterodimer binds to the peroxisome proliferator responsive element (PPRE) on the target 
gene; and 5. Specific gene expression occurs, whose products act intra- or extracellularly to 
elicit a host of various biological functions. (121) 
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Figure 2.3 Observations from the present study in relation to previously suggested and 
approved mechanisms underlying the trans-10, cis-12-CLA-induced lipodystrophic 
alterations in rodents (5). 
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CHAPTER 3 
Methodology 
Animals, diets, and sampling 
Male CD-1 mice from Harlan (Madison, WI), aged 3- to 4-week-old, were 
divided into two experimental groups of ten mice each. The mice were housed individually 
with access to food and water at all times. A 12-h light/12-h dark cycle was maintained 
throughout the study. For 7 d before the start of the study, all mice were fed Harlan Teklad 
(Harlan, Madison, WI) Global Rodent Diet (2018) (18% protein, 5% fat) with 3% (w/w) 
high-oleic sunflower oil added. On day 1 of the study, mice were randomly assigned to 
receive diets containing 3.0% high-oleic sunflower (control) or 2.70% high-oleic sunflower 
oil + 0.30% trans-10, cis-12-CLA. The free FA form of trans-10, cis-12-CLA (>95% purity) 
was obtained from Natural Lipids (Hovdebygda, Norway). Mice were fed daily at 16.00 
hours, and food refusals were weighed to estimate intake during the previous 24 h. Samples 
of each diet were obtained each week and stored at 4℃ prior to FA analysis. Table 3.1 gives 
an overview of the FA composition of the diets fed to growing male mice. Data on body 
weight, feed intake, and tissue fatty acid profiles have been published previously (24). 
At the end of weeks 2 and 6, five mice per dietary treatment were anesthetized 
with Metofane ® (Pitman-Moore, Inc, Washington Crossing, NJ) prior to cervical 
dislocation. The liver was removed, rinsed with diethlpyrocarbonate (Sigma, St. Louis, MO) 
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in distilled water (1:1000, v/v), and weighed. A portion of liver was frozen in liquid nitrogen 
and stored at -80℃ prior to RNA extraction and gene expression analysis. The remainder of 
the liver was stored at -20℃ prior to FA analysis, which is reported in the previous study 
(24). 
 
Extraction and analysis of RNA and semiquantification by RT-PCR 
Liver RNA was extracted using TRI REAGENT
®
 (MRC, Cincinnati, OH) and 
according to the manufacturer’s instructions. Genomic DNA was removed from RNA with 
DNase (Qiagen) using RNeasy Mini Kit columns (Qiagen, Germany). RNA concentration 
was measured with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). 
The purity of RNA (A260/A280) for all samples was above 1.8. RNA quality was assessed 
using a 2100 Bioanalyzer (Agilent Technologies). A portion of assessed RNA was diluted to 
100 ng/μl using DNase-RNase free water prior to reverse transcriptase. 
Each cDNA was synthesized by RT-PCR using 100 ng RNA, 1 μl dT18 (Operon 
Biotechnologies, AL), 1 μl 10 mmol/L dNTP mix (Invitrogen Corp., CA), 1 μl random 
primers (Invitrogen Corp., CA), and 10 μl DNase/RNase free water. This mixture was 
incubated at 65℃ for 5 min and kept on ice for 3 min. A total of 6 μl of Master Mix 
composed of 4.5 μl 5X First-Strand Buffer, 1 μl 0.1 M DTT, 0.25 μl (50u) of SuperScriptTM 
III RT (Invitrogen Corp., CA), and 0.25 μl of RNase Inhibitor (10U, Promega, WI) was 
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added. The reaction was performed in an Eppendorf Mastercycler
®
 Gradient using the 
following temperature program: 25℃ for 5 min, 50℃ for 60 min, and 70℃ for 15 min. 
cDNA was the diluted 1:4 with DNase/RNase free water. 
Quantitative PCR (qPCR) was performed using 4 μl of diluted cDNA combined 
with 6 μl of a mixture composed of 5 μl 1× SYBR Green master mix (Applied Biosystems, 
CA), 0.4 μl each of 10 μM forward and reverse primers, and 0.2 μl DNase/RNase free water 
in a MicroAmp
TM
 Optical 384-Well Reaction Plate (Applied Biosystems, CA). Each sample 
was run in triplicate and a 5 point relative standard curve plus the non-template control 
(NTC) were used (User Bulletin #2, Applied Biosystems, CA). The reactions were 
performed in an ABI Prism 7900 HT SDS instrument (Applied Biosystems, CA) using the 
following conditions: 2 min at 50℃, 10 min at 95℃, 40 cycles of 15 s at 95℃ 
(denaturation), and 1 min at 60℃ (annealing + extension). The presence of a single PCR 
product was verified by the dissociation protocol using incremental temperatures to 95℃ 
for 15 s plus 65℃ for 15 s. Complete details regarding amplification of target genes can be 
found at http://docs.appliedbiosystems.com/pebiodocs/04364014.pdf. 
 
Selection and evaluation of internal control genes (ICG) 
Data were calculated with the 7900 HT Sequence Detection Systems Software 
(version 2.2.1, Applied Biosystems) using a five-point standard curve, as required for the 
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evaluation of gene stability. Stability (M = gene – stability measure) using geNorm (147) 
refers to the constancy of the expression ratio between two non-co-regulated genes among 
all samples tested. The more stable the expression ratio among two genes, the more likely 
that the genes are appropriate internal controls, i.e. two ideal control genes should have an 
identical expression ratio in all samples regardless of experimental conditions, cell, and/or 
tissue type. The lower the M value, the higher the stability. geNorm also performs an 
analysis to determine the utility of including more than 2 genes for normalization by 
calculating the pairwise variation (V) between the normalization factor (NF) obtained using 
n genes (best references) (NFn) and the NF obtained using n+1 genes (addition of an extra 
less stable reference gene) (NFn+1). A large decrease in the pairwise variation indicates that 
addition of the subsequent more stable gene (i.e. with lowest M value) has a significant 
effect and should be included for calculation of the NF (147). Once the most stable internal 
reference genes are selected, the NF is calculated using the geometrical average between 
them to normalize qPCR data. 
At the beginning, a total of seven genes were selected as internal control genes, 
including β-actin, β2 microglobulin (β-2M), Procollagen-lysine-2-oxoglutarate 
5-dioxygenase 3 (PLOD3), neuroglobin (NGB), Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), sentrin specific peptidase 7 (SENP7), and syntaxin 8 (STX8). 
According to the results generated by geNorm, β-actin, β2 microglobulin (β-2M), 
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Procollagen-lysine-2-oxoglutarate 5-dioxygenase 3 (PLOD3), and neuroglobin (NGB) 
expression data were the four most stable genes among the ones tested as internal controls. 
 
Selection of genes and primer design 
Thirty-eight genes encompassing networks with central biological functions in 
lipid metabolism were evaluated (Figure 1.1). Those genes encode proteins required for 
fatty acid uptake, fatty acid oxidation, de novo fatty acid synthesis, lipolysis, lipogenesis, 
ketogenesis, carbohydrate metabolism, apoptosis, inflammation, stress response, growth 
factor signaling, transcriptional regulation of lipogenesis and lipid droplet formation. 
Primers were designed with Primer Express software fixing the amplicon length to 100-120 
bp with low specific binding at the 3’-end (limit 3’-G+C; Applied Biosystems). Primers for 
the thirty-eight selected genes and the four internal control genes are shown in Table S2. 
Primers were aligned against publicly available databases using BLAST software at the 
National Center of Biotechnology Information and also UCSC’s Mouse Genome Browser 
Gateway 
(http://genome.ucsc.edu/cgi-bin/hgGateway?hgsid=183612843&clade=mammal&org=Mou
se&db=0). Prior to qPCR, primers were tested by semiquantitative PCR using a total of 20 
μl mixture composed of 8 μl pooled cDNA, 10 μl SYBR Green, 1μl each of forward and 
reverse primers. The PCR reaction was set to 2 min at 50℃, 10 min at 95℃, 40 cycles of 15 
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s at 95℃ (denaturation). PCR products were run in a 3% agarose gel (Invitrogen) stained 
with ethidium bromide. PCR products were sequenced at the Core DNA Sequencing 
Facility of the Roy J. Carver Biotechnology Center at the University of Illinois, 
Urbana-Champaign. Aliquots of all PCR products are stored to enable additional 
confirmatory sequencing of PCR products in the future if required. 
 
Gene network analysis 
Gene networks were evaluated using Ingenuity Pathway Analysis
®
 (IPA; 
http://www.ingenuity.com), Redwood City, CA). This is a web-based application that 
enables the discovery, visualization, and exploration of interaction networks. The software 
relies on currently known relationships (i.e., published manuscripts) among human, mouse 
and rat genes/proteins. 
 
Statistical analysis 
Data were analyzed as a completely randomized design with a factorial 
arrangement of treatments using the MIXED procedure of SAS
®
 (Windows version 9.1, 
Cary, NC). Interaction was dietary treatment × week. Leastsquare means ± SEM (combined 
observations for weeks 2 and 6) are presented in tables and figures. 
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Relative mRNA abundance among transcripts 
Efficiency of PCR amplification for each gene was calculated using the standard 
curve method (E = 10
-1/-log curve slope
). Relative mRNA abundance among measured genes was 
calculated as reported by Bionaz et al. (148), using the inverse of PCR efficiency raised to 
ΔCt (gene abundance = 1/EΔCt, where ΔCt = Ct sample – geometric mean Ct of 4 internal 
control genes). Overall mRNA abundance for each gene among all samples measured was 
calculated using the median ΔCt. Use of this technique for estimating relative mRNA 
abundance among genes was necessary because relative mRNA quantification was 
performed using a standard curve (made from a mixture of RNA from several mouse tissues, 
which precluded a direct comparison among genes. Together, use of Ct values corrected for 
the efficiency of amplification plus internal control genes as baseline overcome this 
limitation. Description of genes measured and overall % relative mRNA abundance are 
reported in Table 1.1. 
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Table 3.1 Fatty Acid Composition of Diets Fed to Growing Male Mice for 6 Wk 
 
Fatty Acid 
trans-10, cis-12-CLA 
0% 0.30% 
10:0 0.02 0.02 
12:0 0.04 0.05 
14:0 0.12 0.12 
16:0 9.26 9.18 
cis-9-16:1 0.18 0.19 
18:0 2.49 2.52 
trans-11-18:1 0.02 0.02 
cis-9-18:1 34.41 31.77 
18:2n-6 47.34 46.28 
cis-9, trans-11-18:2 0.02 0.32 
trans-10,cis-12-18:2 0.00 2.67 
18:3n-3 3.72 3.77 
20:0 0.39 0.38 
20:4n-6 0.02 0.03 
Total (μg/mg of diet) 44.07 46.14 
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CHAPTER 4 
Results and Discussion 
Data from this study published previously (24) observed a reduced deposition of 
lipids in peripheral tissues as well as a 15-18% increase in liver weight of male mice in 
response to relatively low amounts of trans-10, cis-12-CLA in a dose-dependent manner; 
and, the increased liver weight was accompanied by an increase in hepatic total fatty acid 
content. Apart from our previous study, many other studies have shown that trans-10, 
cis-12-CLA increases liver weight and reduces adipose mass; and, those studies that also 
measured the hepatic TG content, hepatic enlargement was associated with a 3- to 7-fold 
increase in TG content as summarized in Table 4.2. In the present study, we examined a 
total of thirty-eight genes related to lipid metabolism using real-time PCR in the livers of 
mice fed trans-10, cis-12-CLA, aiming to explore the underlying cellular and molecular 
mechanisms causing increased liver weight and potentially impaired function. The results of 
hepatic gene expression in response to trans-10, cis-12-CLA were listed in Table 4.3-4.5. 
 
Trans-10, cis-12-CLA increased fatty acid uptake in the liver 
Accumulating evidence suggests that an increase in lipogenesis and esterification 
due to dietary trans-10, cis-12-CLA is primarily responsible for liver triacylglycerol (TG) 
accumulation (33, 124, 129). Liver TG accumulation also could be a result of increased 
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hepatic uptake of circulating non-esterified fatty acids (NEFA) (149). In a study conducted 
by Gruffat et al., liver tissue samples of rats were incubated with 0.75 mM of fatty acid 
mixture (representative of circulating NEFA) and with 55 μM trans-10, cis-12-CLA or 
oleate. They found that the uptake of CLA by hepatocytes was three times higher (p < 0.01) 
than for oleate (150). Passive diffusion of fatty acid across membranes plays a minor role 
compared with protein-mediated fatty acid uptake and the flip-flop mechanism (151). The 
main proteins involved in fatty acid uptake in non-ruminant cells include fatty acid 
translocase Fat/Cd36 (Cd36) (152) and fatty acid transport proteins (Slc27a) (153). Slc27a2 
is a member of the family of fatty acid transport proteins (FATPs) (151) and is 
predominantly expressed in liver and kidney (153).Serum NEFAs traverse into the 
hepatocytes mainly by interaction of the NEFAs directly with Slc27a2 or by a preceding 
binding to cell-surface proteins, such as Cd36, which subsequently hands the NEFAs to 
Slc27a2 (151).  
In the present study, Cd36 mRNA abundance accounted for 0.0005% whereas 
Slc27a2 accounted for 3.63% of total genes measured. However, Cd36 mRNA expression 
(CLA = 1.11, control = -1.47; p = 0.001) was greater with trans-10, cis-12-CLA treatment 
and there was no change for Slc27a2 expression (CLA = -0.04, control = -0.23; p = 0.42). 
The increased Cd36 expression suggests that trans-10, cis-12-CLA caused more NEFAs 
uptake into hepatocytes, which was in agreement with a higher hepatic FFA content 
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(two-fold) (25) as well as a lower serum FFA concentration in mice fed trans-10, 
cis-12-CLA (31). Furthermore, a previous study showed not only a significant increase in 
hepatic Cd36 expression in mice fed trans-10, cis-12-CLA, but also significant association 
between Cd36 expression and the degree of hepatic steatosis (154). Therefore, upregulation 
of Cd36, although not the most abundant NEFA transporter, is part of the mechanism 
leading to increased hepatic fatty acid uptake and hepatic steatosis induced by trans-10, 
cis-12-CLA. 
 
Trans-10, cis-12-CLA stimulates lipogenesis and TG synthesis in liver 
Acaca and de novo fatty acid synthesis 
Several authors suggested that de novo fatty acid synthesis may play a role in the 
onset of hepatic steatosis related to CLA supplementation (124, 129). Acetyl-CoA 
carboxylase (Acc) is one of the two enzymes required for long-chain fatty acid (LCFA) 
synthesis; the other is Fasn (155). ACC catalyzes the carboxylation of acetyl-CoA to 
generate malonyl-CoA, which is the committed step in this pathway (155). Two forms of 
Acc have now been identified: Acc-α (Acaca) and Acc-β (155). Acaca is involved in the 
synthesis of LCFAs, while Acc-β may be involved in the regulation of mitochondrial 
oxidation of fatty acids (156).  
In our study, mRNA abundance of this gene accounted for 0.52% of total genes 
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measured. We observed that hepatic Acaca expression was significantly up-regulated (CLA 
= 0.72, control = 0.22; p = 0.0027) in response to trans-10, cis-12-CLA, suggesting that the 
liver was generating more malonyl-CoA which was then used for palmitic acid synthesis by 
the multifunctional enzyme Fasn (155). Results from Ashwell et al. (32) and Kelley et al. 
(25) support this hypothesis by observing more C16:0 in liver tissue of obese mice fed 
trans-10, cis-12-CLA than those fed a LA or corn oil diet. 
However, there are some studies showing no significant changes in hepatic Acaca 
expression in mice fed trans-10, cis-12-CLA. In a study conducted by Ashwell et al., 
feeding mice 1% trans-10, cis-12-CLA for 14 days resulted in accumulation of 62.5% more 
fat in livers and a 33% increase in liver weight (32). They surprisingly found Acaca and 
other genes involved in fatty acid and glycerol lipid synthesis and/or degradation were not 
impacted by trans-10, cis-12-CLA (32). Zabala et al. also pointed out that trans-10, 
cis-12-CLA (5g/kg diet for 6 weeks) increased liver weight but reduced hepatic TG content 
without affecting mRNA levels and the activities of several lipogenic enzymes, including 
Acaca, in hamsters (114). In that study, the increased liver weight might be due to a 
significant increase in hepatocytes number (23% p < 0.01) instead of excessive fat 
accumulation (MT Macarulla, A Fernández-Quintela, A Zabala, V Navarro, E Echevarria, I 
Charruca, VM Rodríguez and MP Portillo, unpublished results). These findings suggest the 
existence of a species-specific response of liver to CLA feeding (112). 
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Moreover, although our study observed an upregulation of Acaca in mice fed 
trans-10, cis-12-CLA, increasing fate of fatty acid synthesis by stimulating Acaca may not 
guarantee that the fatty acids will be diverted towards TG biosynthesis (157), because the 
fatty acids may be used either for biosynthesis of TG or for degradation via β oxidation in 
the mitochondrial matrix (157). 
 
Scd and TG synthesis 
Stearoyl-CoA desaturase (Scd) is the rate-limiting enzyme involved in the 
synthesis of mono unsaturated fatty acids (16:1 or 18:1) from saturated fatty acids (16:0 or 
18:0) (158). Although not in the G3P pathway of TG synthesis, Scd plays an important role 
in the synthesis of TG (158). A proper ratio of saturated to monounsaturated fatty acids 
contributes to membrane fluidity and alterations have been implicated in a variety of disease 
states (159). The expression of the mouse Scd gene is regulated by PUFAs and cholesterol 
at the levels of transcription and mRNA stability (160). Many studies have showed that Scd 
mRNA expression in adipose tissue decreased as the trans-10, cis-12-CLA content of the 
diet increased (5, 24). 
We observed a significant upregulation of expression of Scd (CLA = 0.05, control 
= -0.92; p = 0.0007) in the liver of the mice fed trans-10, cis-12-CLA. mRNA abundance of 
Scd accounted for 2.53% of total genes measured. Guillen et al. supported our finding by 
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observing an increase in hepatic Scd expression in mice fed trans-10, cis-12-CLA (154). 
Moreover, they indicated that Scd had a significant association with the degree of hepatic 
steatosis (154). Because a large number of studies have shown that trans-10, cis-12-CLA 
reduces fat mass considerably, the upregulation of hepatic Scd mRNA due to feeding 
trans-10, cis-12-CLA may be a response to greater influx of 16:0 and 18:0 derived from 
adipose tissue. Moreover, the increased in de novo fatty acid synthesis via up-regulation of 
hepatic Acaca expression also may have contributed indirectly to the greater hepatic Scd 
expression. Together with the up-regulation of Gpam expression in the liver (discussed as 
below), trans-10, cis-12-CLA-induced hepatic steatosis may, at least in part, be attributed to 
stimulated lipogenesis and esterification. Our result was in agreement with the findings 
from previous studies (5, 32) which measured the ratio of saturated to monounsaturated 
fatty acids as an indicator of the enzymatic activity of Scd. 
 
GPAM and TG synthesis 
In the glycerol phosphate pathway to synthesize TG, acyl-chains from acyl-CoA 
are transferred consecutively to G3P produced either via glyceroneogenesis or through 
phosphorylation of glycerol released from adipose tissue during lipolysis (161). This 
reaction is catalyzed by G3P acyltransferase (Gpam) which resides in the outer 
mitochondrial membrane (162), and it is the first committed step in the synthesis of TG 
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(162, 163) via the glycerol phosphate pathway. Besides, Gpam is an enzyme that can switch 
the fate of fatty acids from β oxidation to glycerolipid synthesis (164, 165).  
In our study, Gpam mRNA abundance accounted for 3.18% of total transcripts 
measured. Although a previous study found that trans-10, cis-12-CLA did not change 
statistically the hepatic expression of Gpam in mice (32), we observed a marked increase in 
hepatic Gpam expression (CLA = 0.44, control = -0.31; p = 0.003) in mice fed trans-10, 
cis-12-CLA, which was suggestive of stimulation of esterification in order to synthesize TG 
in liver. It could be possible that the concerted upregulation of both Acaca and Gpam was a 
mechanistic response to promote biosynthesis of TG, e.g. the up-regulation of Acaca 
stimulated de novo fatty acid synthesis, thus, generated more precursor for TG synthesis and 
resulting in increased Gpam expression. 
Moreover, there is a potential that blood NEFAs derived and exported from 
adipose tissue went into liver and most of them would be esterified into TG via Gpam. From 
this point, synthesis of TG under catabolic conditions (i.e. as it would occur during lipolytic 
stimulation) is not a result of lipogenesis but esterification of blood derived NEFA and 
lower rates of oxidation of fatty acids to ketones and carbon dioxide. All in all, our results 
supported the hypothesis that trans-10, cis-12-CLA-induced lipogenesis and esterification 
are primarily responsible for liver TG accumulation (33, 124, 129). 
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Dgat1, Dgat2 and TG synthesis 
There are two major biochemical pathways for TG synthesis: the 
monoacylglycerol (MAG) pathway and the G3P pathway (166). The former pathway plays 
a predominant role in the enterocytes (167) and adipose tissue (168), while the latter is a de 
novo pathway in most tissues. These two pathways share the final step in converting 
diacylglycerol (DG) to TG, a reaction catalyzed by diacylglycerol acyltransferase (Dgat) 
(158, 169). Yamazaki et al. found that Dgat1 is located in the lumen of the endoplasmic 
reticulum and promotes VLDL secretion, while Dgat2 has potent Dgat activity and plays a 
key role in cytosolic lipid accumulation; Dgat2 overexpressing mice had a 3.1-fold increase 
in hepatic fat content (170). In line with this observation, in high-fat fed obese mice 
liver-specific Dgat2 inhibition caused a marked reduction in hepatic TG content and plasma 
lipid levels (171).  
In the present study, Dgat1 mRNA abundance accounted for 0.15%, whereas 
Dgat2 mRNA abundance accounted for 4.93% of total genes measured. We observed 
numerical increases in the hepatic expression of Dgat1 (CLA = 0.30, control = -0.02; p = 
0.18) and Dagt2 (0.25, control = 0.03; p = 0.30) in the mice fed trans-10, cis-12-CLA. 
Although there was substantial variation in the expression of Dgat2 among animals, it could 
be speculated that this increase in Dgat2 mRNA expression corresponded to an actual 
metabolic requirement for stimulating TG synthesis. Such response has been clearly 
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observed in numerous studies with trans-10, cis-12-CLA that resulted in  liver enlargement 
(25, 28-32, 113) (See Table 4.2). 
 
Trans-10, cis-12-CLA stimulated glyceroneogenesis in liver 
Pck1 and gluconeogenesis and glyceroneogenesis 
Phosphoenolpyruvate carboxykinase 1 (Pck1) catalyzes the rate-limiting step in 
the gluconeogenesis pathway, converting oxaloacetate to phosphoenolpyruvate (172). In 
addition, Pck1 also is important for generation of G3P during the process of 
glyceroneogenesis which under most physiological circumstances is the predominant 
pathway to generate the glycerol backbone for TG synthesis (173). Pck1 mRNA abundance 
accounted for 14.79% of total genes measured. We observed a significant increase in 
hepatic Pck1 expression (CLA = -0.29, control = -1.74; p = 0.05) in mice fed trans-10, 
cis-12-CLA, which was indicative of increased glyceroneogenesis and/or gluconeogenesis 
in liver. Although we did not measure the plasma insulin level in mice, the trans-10, 
cis-12-CLA-induced hyperinsulinemia with a normal range of blood glucose level 
demonstrated by Clément et al. (33) would inhibit gluconeogenesis via Pck1. Furthermore, 
a greater degree of glyceroneogenesis would agree with the greater expression of Gpam. 
Therefore, this could contribute to enhanced TG synthesis and accumulation in liver due to 
trans-10, cis-12-CLA. 
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Pdk4 and glucose metabolism 
The pyruvate dehydrogenase complex (PDC) catalyzes the irreversible oxidative 
decarboxylation of pyruvate into acetyl-CoA (174). Regulating PDC is an important step in 
fuel selection of energy utilization in animals during different nutritional and hormonal 
states as the modulation of PDC activity impacts fatty acid as well as pyruvate and glucose 
metabolism (175). Phosphorylation of PDC via pyruvate dehydrogenase kinase (Pdk) 
inhibits its activity (175, 176), thereby reducing the conversion of pyruvate to acetyl-CoA 
(177). Four isoenzymes of Pdk have been identified in mammalian tissues, including Pdk1, 
Pdk2, Pdk3 and Pdk4 (176). The abundance of the Pdk4 isoform, which is highly expressed 
in liver, heart and skeletal muscle, is transcriptionally controlled (178).  
Pdk4 mRNA abundance accounted for < 1% of total genes measured. In our study, 
the group fed with trans-10, cis-12-CLA had significantly higher hepatic Pdk4 expression 
(CLA = 0.47, control = -1.85; p = 0.001) compared to the control mice, indicative of 
reduced glucose oxidation. Since expression of the Pdk4 gene is induced by high fat diets 
and long chain fatty acids (179), the results may suggest that increased Pdk4 expression 
could be the consequence of trans-10, cis-12-CLA intake. 
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Trans-10, cis-12-CLA enhanced lipid droplet formation in the liver 
Plin and lipid droplet formation 
Perilipin (Plin) proteins are vital for cytoplasmic lipid droplet (LD) formation and 
also lipolysis (180). In isolated hepatocytes, as well as livers from mice and humans, Plin2 
levels are proportional to hepatic lipid content (181); however, it is unclear if increased 
Plin2 is a cause or consequence of fatty liver (182). Importantly, the Plin2 knockout mice 
display a 60% reduction in hepatic TG and are resistant to diet-induced fatty liver (183). To 
determine the mechanism for the reduced hepatic TG content, that study measured hepatic 
lipogenesis, VLDL secretion, and lipid uptake and utilization, all of which were shown to be 
similar between mutant and wild-type mice (183). The finding of similar VLDL output in 
the presence of a reduction in total TG in the Plin2 knockout liver was explained by 
retention of TG in the microsomes where VLDL is assembled. Given that LDs are thought 
to form from the outer leaflet of the microsomal membrane, the reduction of TG in the 
cytosol with concomitant accumulation of TG in the microsome of Plin2 knockout cells 
suggested that Plin2 facilitates the formation of new LDs (183). 
In our study, expression of Plin2 mRNA accounted for 1.61%. We found that the 
hepatic expression of Plin2 in the mice fed trans-10, cis-12-CLA was significantly 
up-regulated (CLA = 0.40, control = -0.43; p = 0.0017). Since Plin2 may play a role in 
facilitating the formation of new LDs (183), the up-regulation of Plin2 was suggestive of 
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enhanced formation of hepatic LDs in mice fed trans-10, cis-12-CLA, thereby, at least in 
part, contributing to TG accumulation and hepatic steatosis. This may be explained by its 
specific role in the early stages of lipid droplet formation (182). Therefore, we suggest that 
enhanced LD formation via up-regulated expression of Plin2 could be a novel mechanism 
of trans-10, cis-12-CLA’s hepatic steatotic effect on liver. 
 
Trans-10, cis-12-CLA increased VLDL assembly and secretion 
Apob, Mttp and VLDL assembly/secretion 
In the liver, synthesized TG is either stored in cytoplasmic droplets or secreted as 
VLDL particles (170). Most de novo synthesized TG is stored in cytosolic TG pools and a 
smaller portion is secreted in the form of VLDL. Cytosolic TG pool size has been shown to 
correlate with VLDL secretion. Apo-protein B 100 (Apob) is the key component whose rate 
of synthesis in the rough endoplasmic reticulum controls the overall rate of VLDL 
production (184). Lipid components are added to apoprotein B (185) by microsomal TG 
transfer protein (Mttp) (186). Then the apoproteins are glycosylated in the Golgi apparatus 
(184) where secretory vesicles bud off, migrate to, and fuse with the membrane of the 
hepatocytes and release the VLDL into blood (184). Since Mttp catalyzes the transfer of 
lipids to the apoB molecule, Mttp may play a crucial role in the assembly and secretion of 
VLDL in the liver (187). Patients with abetalipoproteinemia have a defect in the Mttp gene 
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resulting in severely deficient lipoprotein secretion (188). Furthermore, Mttp inhibitors can 
reduce the production of apoB-lipoproteins in both hepatoma cell cultures (189-191) and in 
vivo in a rabbit model of human homozygous familial hypercholesterolemia (192). Minehira 
et al. showed that in mouse liver, mutant Mttp gene (homozygous knockout) increases 
hepatic steatosis in mouse (193).  
Both Lin et al. and Yotsumoto et al. indicated that trans-10, cis-12-CLA reduced 
both apoB synthesis and TG secretion in HepG2 cells (144, 146). Several in vivo studies (31, 
48, 113) observed reduced plasma TG levels in mice fed trans-10, cis-12-CLA, supporting 
the findings from in vitro studies. In contrast, when it comes to clinical studies, previous 
short-term studies in humans have revealed varying effects of CLA on blood lipids. 
Whigham et al. (120) found increased plasma TG levels in subjects receiving 6 g/d of CLA 
mixture (trans-10, cis-12-CLA: cis-9, trans-11-CLA = 1:1) after 28 and 52 weeks of feeding 
compared with controls. In contrast, Iwata et al. observed no significant changes in blood 
TG from Japanese male volunteers receiving low or high CLA mixtures or control (119). 
Another study found a reduction of VLDL-TG and TG in the blood in human subjects 
receiving 3 g/d of CLA mixture (trans-10, cis-12-CLA: cis-9, trans-11-CLA = 1:1) for 8 
weeks (194). 
In our study, Apob mRNA abundance accounted for 9.14% and Mttp mRNA 
abundance accounted for 1.24% of total genes measured; however, we observed a numerical 
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increase in Apob expression (CLA = -0.05, control = -0.33; p = 0.29) and a significant 
up-regulation of expression of Mttp (CLA = 0.14, control = -0.37; p = 0.04) in the mice fed  
trans-10, cis-12-CLA. Despite the apparent accumulation of TG in the liver (24) leading to 
greater weight (Table 4.1), our results suggest that the VLDL assembly/secretion 
mechanism in mice fed trans-10, cis-12-CLA was not impaired and may have actually been 
enhanced via the up-regulation of hepatic Mttp. It was reported previously that in trans-10, 
cis-12-CLA-fed mice the VLDL secretion rate was increased; whereas, the plasma TG 
concentration was decreased (30). Together with our results, studies suggest that TG-rich 
lipoproteins and NEFAs are taken up in the trans-10, cis-12-CLA-fed animals  to such an 
extent that the VLDL secretion rate, even when increased, is insufficient to eliminate excess 
fatty acid (Table 4.1) entering the whole esterification and VLDL assembly/secretion 
pathways, which would account for part of the fat deposit within liver cells. 
Furthermore, our findings were in agreement with recent kinetic studies. They 
have pointed out that the actual amount of hepatic TG-rich lipoprotein secretion rate in 
non-alcoholic fatty liver disease is actually increased, but is inadequate to match the 
increased TG synthesis in the liver (195). One of those studies found that subjects with 
NAFLD failed to further increase VLDL-TG secretion rate when hepatic TG infiltration 
exceeded 10% suggesting the liver of these subjects had a limited capacity to secrete VLDL 
particles (195). 
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Cideb and VLDL secretion 
The cell death-inducing DFF45-like effector (Cide) family of proteins consists of 
three molecules, including Cidea, Cideb and Cidec/fat specific protein 27 (Fsp27) (196). 
Mouse Cideb is mainly expressed in liver and kidney (197). Recently, Li et al. observed that 
liver of Cideb null mice had higher levels of TG accompanied by lower levels of VLDL 
secretion (198). They also found that Cideb is localized to smooth ER and LDs and 
identified apoB as a Cideb-interacting protein (198). By infecting adenoviruses expressing 
various Cideb truncations into hepatocytes of Cideb-null mice, they found that Cideb 
requires both its apoB-binding and LD association domains to restore the secretion of 
TG-enriched VLDL particles (198). Their data suggest that Cideb promotes the formation of 
TG-enriched VLDL particles (198).  
Cideb mRNA abundance accounted for 3.46% of total genes measured in the 
present study and its expression in mice fed trans-10, cis-12-CLA was significantly 
up-regulated (CLA = -0.04, control = -1.13; p = 0.05). The greater expression of Cideb in 
the liver suggested more effective TG secretion via VLDL and underscored that hepatic 
steatosis induced by trans-10, cis-12-CLA was not due to impaired VLDL secretion. 
However, given the increased liver weight, the increase in VLDL secretion might be 
insufficient to eliminate the fatty acid (Table 4.1) entering the whole esterification and 
VLDL assembly/secretion pathways. 
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Transcription regulation and lipogenesis and TG synthesis 
Srebf1-related networks and TG synthesis 
Sterol regulatory element binding transcription factor 1 (Srebf1), also known as 
sterol regulatory element-binding protein 1 (Srebp1), is a transcription factor involved in 
hepatic lipogenesis and also adipocyte differentiation (199, 200) . It is predominantly 
expressed in liver and adipose tissue (201-203). Srebf1 is synthesized as a precursor protein 
and is released from the ER membrane into the nucleus as a mature protein by a sequential 
cleavage process to bind sterol regulatory elements and then activate expression of the 
target genes (204, 205), such as Acaca (206) and Scd1 (207). Overall, Srebf1 plays a central 
role in energy homeostasis by promoting glycolysis, lipogenesis, and adipogenesis (208).  
Srebf1 mRNA abundance accounted for 0.67% of total genes measured in our 
study. The hepatic Srebf1 expression in mice fed trans-10, cis-12-CLA was significantly 
up-regulated (CLA = 0.14, control = -0.22; p =0.02), which was in agreement with previous 
published reports indicating that a CLA-mix diet significantly induced the Srebf1 
expression in the murine liver (33, 209). In freshly-isolated hepatocytes, Srebf1c mRNA 
was activated by insulin (210). Thus, the up-regulated Srebf1 gene in our study may have 
been a response to higher levels of insulin in mice fed trans-10, cis-12-CLA which has been 
previously reported by Clément et al, Halade et al. and Tsuboyama-Kasaoka et al (22, 33, 
48). In our study, the expression of Srebf1’s target genes, including Acaca, Scd, and Gpam 
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(206), were all significantly up-regulated in mice fed trans-10, cis-12-CLA, which suggests 
that the liver was generating more palmitic acid, oleic acid and TG (211). Collectively, these 
results indicate that trans-10, cis-12-CLA stimulates the lipogenic pathway by indirectly 
up-regulating Srebf1, leading to an overall increase in fat accumulation in liver. 
 
Chrebp and lipid metabolism 
Carbohydrate response element binding protein (Chrebp) is a transcription factor 
responsible for glucose-induced transcription of liver pyruvate kinase (LPK) gene (212). 
Some studies provided evidence for a direct and dominant role of Chrebp in the glucose 
regulation of two key liver lipogenic enzymes, Acaca and Fasn, therefore Chrebp is also 
known to be major regulator of lipogenic enzymes (157, 213). Chrebp is expressed 
constitutively in hepatocytes (214) and is known to recognize E box sequences in the 
promoters of target genes (215). The regulation of Chrebp involves 
phosphorylation-dependent mechanisms responsive to feeding (glucose and fatty acids) and 
fasting (glucagon) (216). Under low glucose conditions, Chrebp remains in the cytosol and 
unable to bind DNA as the result of phosphorylation at multiple sites (214). The 
dephosphorylation of Chrebp in response to high glucose does not require insulin (213).  
In our study, Chrebp mRNA was numerically up-regulated (CLA = -0.17, control 
= -0.22; p = 0.62). Chrebp mRNA abundance accounted for 2.83% of total genes measured. 
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However, some of its target genes involved in lipid metabolism in the liver were 
significantly up-regulated, including Acaca and Gpam, suggesting that trans-10, 
cis-12-CLA indirectly stimulated lipogenic genes through Chrebp as well as Srebf1. 
 
Pparα and lipid catabolism 
The ligand-activated transcription factor, peroxisome proliferator-activated 
receptor α (Pparα), modulates lipid catabolism via specific Ppar responsive elements 
(PPREs) in the regulatory regions of genes such as lipoprotein lipase (134), Acox1 (217), 
Cpt1, thioesterases, fatty acid binding protein, peroxisomal and mitochondrial β oxidation 
enzymes, microsomal ω-oxidizing enzymes and apolipoproteins (131). Peroxisome 
proliferators (PPs) activate Pparα which then heterodimerises with RXR and binds to DNA 
at PPREs upstream of PP responsive genes (218). Activation of Pparα by ligands results in 
altered transcription of many of these genes which may stimulate fatty acid uptake and 
activation, mitochondrial oxidation, peroxisomal fatty acid oxidation, ketogenesis, and fatty 
acid elongation and desaturation (219). 
Isomers of CLA have some structural features similar to PPs and importantly the 
physiological responses observed in mice (reduced body weights, hepatic lipid 
accumulation, hypolipidemia) are characteristic of this group of chemicals (134). As 
trans-10, cis-12-CLA has been reported to be a potent ligand of Pparα (134), the underlying 
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regulations might imply the activation of Pparα. In our study, the hepatic Pparα expression 
(CLA = -0.19, control = -0.33; p = 0.42) in mice fed trans-10, cis-12-CLA was numerically 
higher than in the control group. Pparα mRNA abundance accounted for 1.28% of total 
genes measured. Although no significantly up-regulation of Pparα was observed in our 
study, many of its target genes playing important roles in lipid metabolism (Cd36, Plin2, 
Scd, Pck1, Pdk4, Acox1, Ucp2 and Srebf1) were significantly up-regulated, providing 
indirect evidence that trans-10, cis-12-CLA might act through Pparα. 
 Despite dietary trans-10, cis-12-CLA induced expression of Pparα target genes, 
including fatty acid transporter, Srebp1 and Fasn genes, in vitro transactivation assays 
demonstrated that trans-10, cis-12-CLA and cis-9, trans-11-CLA were equally efficient at 
activating Pparα, thus the specific effect of trans-10, cis-12-CLA is unlikely to result from 
direct interaction with this nuclear receptor (33). In another study, wild-type or Pparα-null 
mice were fed a diet containing 0.5% CLA mixture (trans-10, cis-12-CLA represented 
43.5% of CLA). After 4-week feeding period, while CLA feeding resulted in specific 
activation of Pparα target genes in liver that contribute to increased use of fatty acids as 
substrates and subsequent reductions in body weight/fat content, changes in those Pparα 
target gene expression were found in both wild-type and Pparα-null mice fed CLA (125) 
(125). 
Apart from those, numerous lines of evidence indicate that it has a major role in 
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glucose metabolism (220). First, several studies (221-223) showed that fasting Pparα-null 
mice display marked hypoglycemia. Second, both Guerre-Millo et al. and Tordjman et al. 
found that high-fat feeding-induced insulin resistance in mice was mitigated in the absence 
of Pparα (224, 225). Third, a study found that induction of the gluconeogenic genes Pck1 
and glucose 6-phosphatase by dexamethasone is Pparα dependent (226), although they are 
not direct target genes of Pparα (220). Fourth, Patsouris et al. showed that Pparα decreases 
plasma glycerol levels in mice and humans by directly upregulating the expression of genes 
involved in hepatic gluconeogenesis from glycerol, including cytosolic glycerol 
3-phosphate dehydrogenase (cGpdh), mitochondrial glycerol 3-phosphate dehydrogenase 
(mGpdh), glycerol kinase, aquaporin 3 (AQP3), and aquaporin 9 (AQP9) (220). They also 
pointed out that the stimulatory effect of Pparα on gluconeogenic gene expression is 
associated with elevate hepatic glucose production during fasting (220). Above all, it can be 
concluded that Pparα has an important influence on glucose metabolism. 
 
Trans-10, cis-12-CLA increased fatty acid oxidation in the liver 
Since the decrease in fatty acid oxidation may cause fat accumulation in the liver 
(31), it is intuitive that the mRNA expression of the enzymes related to fatty acid oxidation 
may be down-regulated during liver lipidosis. However, recent investigations of the 
trans-10, cis-12-CLA’s effects on fatty acid oxidation are controversial. Rasooly et al. 
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indicated that trans-10, cis-12-CLA supplementation decreased the expression of genes 
involved in fatty acid oxidation, including flavin monooxygenase-3 (FMO3) (95%, p < 
0.0001), cytochrome P450 (cyt P450) (61%, p = 0.002), Cpt1a (77%, p = 0.025), acetyl 
CoA oxidase (50%, p = 0.08) and Pparα (65%, p = 0.05) (227). However, in the study of 
Gruffat at el., liver tissue samples of rats incubated with a fatty acid mixture (representative 
of circulating NEFA) and trans-10, cis-12-CLA or oleate they found that the rate of CLA 
isomer oxidation was two times higher than that of oleate (p < 0.01) (150). Furthermore, 
expression of mice hepatic fatty acid oxidation genes also increased in three studies with a 
mixture of CLA isomers (124, 129, 228) and in one study with trans-10, cis-12-CLA (31). 
 
Cpt1 and fatty acid oxidation 
Cpt1 is considered the rate-limiting enzyme for mitochondrial β oxidation (227). 
Degrace et al. found an increase in the activity of hepatic Cpt1 in mice supplemented with 
trans-10, cis-12-CLA accompanied by an increase in Acox1 activity and gene expression 
(31). Another study conducted by Viswanadha et al. noted that trans-10, cis-12-CLA 
increased the oxidation of fatty acids in murine hepatic cell lines, as indicated by increased 
expression of mRNA for Cpt1 (229). In our study, trans-10, cis-12-CLA supplementation 
the hepatic expression of Cpt1a (CLA = -0.32, control = -0.43; p = 0.57) was numerically 
greater with CLA. Cpt1a mRNA abundance accounted for 1.91% of total genes measured. 
64 
 
Moreover, malonyl-CoA plays a crucial role in the control of mitochondrial fatty 
acid oxidation through its inhibition of Cpt1 (230). As mentioned in the section discussing 
Acaca and de novo fatty acid synthesis, more malonyl-CoA was generated by up-regulated 
Acaca expression in liver in response to trans-10, cis-12-CLA. As a result, Cpt1 expression 
was supposed to down-regulated or inhibited. However, unexpectedly we observed a 
numerically upregulation of Cpt1 expression in liver. 
 
Acox1 and fatty acid oxidation 
Peroxisomes play an important role in lipid catabolism, since very long chain 
fatty acids (VLCFAs) are almost exclusively processed by the peroxisomal β oxidation 
system, whereas fatty acids up to 18 carbons in length are oxidized by the mitochondria 
(231). Acyl-CoA oxidase 1 (Acox1) catalyzes the first and rate-limiting enzyme of the 
peroxisomal fatty acid β oxidation pathway of VLCFAs (232). The reduction of the activity 
and/or mRNA of fatty acid oxidation enzymes in peroxisomes could contribute to the lipid 
accumulation in hepatocytes and to the severity of steatohepatitis. Fan et al. found that mice 
lacking the peroxisomal Acox1 gene developed severe steatohepatitis, lipogranulomas and 
hepatocellular carcinomas (233). Acox1 mRNA abundance accounted for 6.83% of total 
genes measured in our study and we found that mice fed trans-10, cis-12-CLA had greater 
Acox1 expression (CLA = 0.13, control = -0.22; p = 0.05), suggesting increased fatty acid β 
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oxidation in peroxisomes. The up-regulation of Acox1 might be due to the relatively lower 
amount of dietary trans-10, cis-12-CLA supplementation compared with previous studies 
(22, 23, 28, 32, 34-36).  
A study conducted by Clément et al. showed that mice fed a diet enriched in 0.4% 
(w/w) trans-10, cis-12-CLA for 4 weeks developed fatty liver and observed a dramatic 
increase in non fasting plasma insulin levels which were 10 times higher in these mice than 
those fed control (33). Despite this marked hyperinsulinemia, they also pointed out that 
plasma glucose concentration remained within the normal range in these mice fed trans-10, 
cis-12-CLA (33). Thus, they suggest that the train of events leading to trans-10, 
cis-12-CLA-induced alterations in liver is probably indirect and that the liver steatosis 
occurring in trans-10, cis-12-CLA-fed mice is secondary to hyperinsulinemia which causes 
high levels of fatty acid uptake and synthesis (33). 
In our study, the up-regulation of Acox1coupled with the lack of change in Cpt1 
mRNA expression indicated that decreased fatty acid oxidation could not be the factor 
triggering hepatic steatosis (Table 4.1), but might be a consequence of it. Under 
hyperinsulinemia condition, the effect of elevated β oxidation due to trans10, cis-12-CLA 
was overwhelmed by an increase in uptake of fatty acids as well as greater lipogenesis in 
liver, thereby resulting in hepatic steatosis as observed previously (24). 
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Trans-10, cis-12-CLA stimulated ketogenesis in the liver 
Hmgcs2 and ketogenesis 
Under conditions of increased fatty acid uptake and low blood insulin to glucagon 
ratio, the liver often produces large amounts of the ketone bodies, acetoacetate and 
β–hydroxybutyrate, in a process known as ketogenesis (184). Moreover, ketogenesis is 
controlled indirectly by Cpt1 (234) and directly by the activity of the mitochondrial key 
regulatory enzyme 3-hydroxy-3-methylglutaryl-CoA synthase 2 (Hmgcs2) (235). 
Conversion of acetyl-CoA to ketone bodies, rather than complete oxidation in the TCA 
cycle, results in the formation of less ATP/mole of fatty acid oxidized, e.g. five time less in 
the case of palmitate (129 vs. 27 ATP/mole, TCA and oxidative phosphorylation in the 
electron transport chain vs. conversion of acetyl-CoA to ketone bodies) (184). Then why 
liver produces ketone bodies? Ketogenesis allows the liver to metabolize about five times 
more fatty acids (for the same ATP yield) and synthesize water-soluble fuels that other 
tissues can use when there is little glucose available (184). 
In the present study, Hmgcs2 mRNA abundance accounted for 13.88% of total 
genes measured, which was the second highest gene expression among all the genes 
determined. Our results support previous findings of greater hepatic Hmgcs2 expression 
(CLA = 0.13, control = -0.16; p = 0.05) in mice fed trans-10, cis-12-CLA, suggesting that 
this CLA isomer induces more ketone body generation in liver, which was in agreement 
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with a previous study showing that the liver of rats fed CLA produced significantly more 
ketone bodies than those of rats fed a linoleic acid-rich diet (236). 
 
Bdh1 and ketone body utilization 
3-hydroxybutyrate dehydrogenase 1 (Bdh1) plays a key role in redox balance and 
energy metabolism since in the presence of NADH, the hepatic Bdh transforms acetoacetate 
into D-3-hydroxybutyrate, which is then transported through the blood stream to peripheral 
tissues, e.g., brain, heart, and kidney (237). Bdh1 mRNA abundance accounted for 3.35% of 
total genes measured. We observed that Bdh1 expression in mice fed trans-10, cis-1-CLA 
(CLA = 0.13, control = -0.20; p = 0.05) was significantly higher compared with the control. 
The increase in Bdh1 expression suggested that more 3-hydroxybutyrate was produced  
from acetoacetate, which was supported by previous findings showing that liver from 
CLA-fed rats produced significantly more ketone bodies and the ratio of 3-hydroxybutyrate 
to acetoacetate was consistently higher in the liver perfusate (236). 
Together with data on Hmgcs2 this was indicative of stimulated ketone body 
production in liver. Indirectly, expression of Hmgcs2 and Bdh1 would support the notion 
that there likely was greater adipose tissue lipolysis in these mice, thus, providing ample 
NEFA for oxidation and ketogenesis. The results suggest that probably due to high rate of 
fatty acid oxidation in the liver, increased generation of acetyl CoA exceeded the capacity of 
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the TCA cycle; as a result, acetyl CoAs were used for ketogenesis and thereby leading to 
increased expression of Hmgcs2 and Bdh1 expression in liver. 
 
Trans-10, cis-12-CLA changes energy metabolism in liver 
Ucp2 and energy metabolism 
Uncoupling proteins (Ucps) belong to a family of mitochondrial anion carriers 
and are present in the mitochondrial inner membrane (238). Ucps dissipate the proton 
gradient by allowing the re-entry of protons into the mitochondrial matrix during oxidative 
ATP generation, resulting in the uncoupling of the respiratory chain and heat production 
(239). Ucp2 isoform shows the widest tissue expression of all Ucps including liver, skeletal 
muscle, heart and kidney (240). In vivo studies indicate that physiological and pathological 
elevation of blood LCFAs resulting from fasting (241-243) or high fat diet (244) induce 
upregulation of Ucp2. Peters et al. demonstrated that dietary CLA increases gene expression 
of Ucp2 in the liver of C57BL/6N mice (125). Ucp2 mRNA abundance accounted for 
0.19% of total genes measured. Our study observed an upregulation of hepatic Ucp2 
expression (CLA = 0.15, control = -0.31; p = 0.002) in mice fed trans-10, cis-12-CLA 
suggesting that the increased Ucp2 mRNA expression may serve as a counterregulatory 
mechanisms to lower cellular ATP levels and decrease metabolic efficiency, thereby 
reducing fat accumulation in the long-term (240). 
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Trans-10, cis-12-CLA and stress response 
        According to the complex mechanisms proposed by Jaudszus et al. (5), the 
anti-adipogenic effect of trans-10, cis-12-CLA may be primarily the consequence of 
pro-apoptotic and pro-inflammatory responses in adipose tissue, including the nuclear factor 
κB (NFκB)-dependent production of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) 
and interleukin-8 (IL-8) (21, 22, 245). These cytokines produced by adipose tissue induce 
the expression of the proteins suppressor of cytokine signaling-3 (SOCS-3) and JNK, which 
can inhibit  insulin signal transduction leading to hyperinsulinemia and insulin resistance 
(21), thereby suppressing lipid synthesis and increasing lipolysis in adipocytes. The 
trans-10, cis-12-CLA-mediated suppression of the transcription factor PPARγ in the adipose 
tissue was suggested to be indirectly responsible for the pro-inflammatory conditions (21, 
246). 
        In our study, the genes associated with inflammation or stress response as listed in 
Table 7 were all numerically up-regulated , a response likely related to the relatively low 
dosage of trans-10, cis-12-CLA that was fed. 
 
Summary 
In our study the excess fatty acid accumulation and greater liver mass in growing 
male mice consuming trans-10, cis-12-CLA seems to be attributed to increased fatty acid 
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uptake, stimulated TG synthesis, and enhanced LD formation in the liver. Guillén et al. 
observed a significant increase in hepatic Cd36 expression in mice fed trans-10, 
cis-12-CLA and demonstrated a significant association between Cd36 expression and the 
degree of hepatic steatosis. Our finding of up-regulation of Cd36 expression in the liver 
supported those earlier results. Hence, the increased hepatic fatty acid uptake could be one 
potential mechanism by which trans-10, cis-12-CLA causes hepatic steatosis, i.e. the 
peripheral action of trans-10, cis-12-CLA leading to adipose tissue catabolism provides 
NEFA which must be metabolized by tissues and primarily liver.  
The greater up-regulation of Acaca, Gpam and Scd mRNAs indicates that 
increased TG synthesis in the liver contributes to hepatic steatosis in mice fed trans-10, 
cis-12-CLA. Furthermore, the up-regulation of Acaca indicated that the increased hepatic 
lipogenesis would be used for biosynthesis of TG via Gpam. Hepatic lipogenesis 
encompasses a complex series of reactions occurring in part in the cytosol and the 
mitochondrial matrix (247). Ferramosca et al. found that the activity of mitochondrial citrate 
carrier (Cic), considered as the bridge connecting these two different cellular compartments, 
was stimulated by a CLA mixture. The consequent increase in citrate efflux from 
mitochondria would supply the cytosol with the carbon source, in the form of acetyl-CoA 
for hepatic lipogenesis (247).  
We also observed a potential for enhanced lipid droplet formation in the liver of 
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the mice fed trans-10, cis-12-CLA. The up-regulation of Plin2 which is vital for 
cytoplasmic lipid droplet formation, suggests that the steatotic effect of trans-10, 
cis-12-CLA may, in part, be achieved by increasing the lipid storage capacity of hepatocytes. 
Therefore, it is suggested that increased fatty acid uptake, stimulated TG synthesis, and 
enhanced lipid droplet formation might together contribute to the hepatic steatotic effect of 
trans-10, cis-12-CLA. 
The mechanisms by which the liver becomes steatotic in response to trans-10, 
cis-12-CLA appear to be complex, since our study found that trans-10, cis-12-CLA induced 
β-oxidation in the peroxisome without changing it in the mitochondria as evidenced by the 
up-regulation of Acox1 and lack of effect on Cpt1. Induced β-oxidation would not be 
associated with lipid accumulation. There are two possibilities to explain these scenarios. 
First, induced β-oxidation in peroxisomes might be a consequence of excess fat 
accumulation in the liver and a favorable mechanism to help consume excess fatty acid 
influx into liver because expression of Pnpla2 (a TG lipase) was numerically greater with 
trans-10, cis-12-CLA. Second, the relatively low level of supplementation of trans-10, 
cis-12-CLA was not enough to impair hepatic β-oxidation which has been observed in the 
study (127) conducted by Rasooly et al. 
Apart from β-oxidation, reduced VLDL assembling/secretion would not be a 
factor triggering hepatic steatosis in the mice fed trans-10, cis-12-CLA. In our study, the 
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expression of Mttp, which plays a crucial role in the assembly and secretion of VLDL in the 
liver, was up-regulated in the mice fed with trans-10, cis-12-CLA; and, hepatic CIDEB 
expression was significantly higher in the mice fed with trans-10, cis-12-CLA than that in 
control mice, indicating more effective TG secretion via VLDL. Thus, hepatic steatosis in 
the mice fed with trans-10, cis-12-CLA would not be due to impaired VLDL 
assembling/secretion.  
The increased VLDL assembling/secretion could be a result of excess TG 
accumulation in liver and the subsequent lipolysis via Pnpla2. However, there is only one 
possibility that the increased VLDL assembling/secretion could be a triggering factor of 
fatty liver, when the VLDL overproduction from the enlarged liver was insufficient to 
eliminate the flux of fatty acids entering the whole esterification and lipoprotein 
assembling/secretion pathway. After being absorbed in hepatocytes, fatty acids must be 
therefore directed towards the esterification pathway. As a result, the increase in Dgat 
mRNA expression in the liver of trans-10, cis-12-CLA-fed mice corresponded to an actual 
metabolic requirement for meeting the excessive flux of fatty acids, which was in agreement 
with the findings from Degrace et al. They also indicated that the flux of lipids permanently 
cleared from blood and taken up more abundantly by a heavier liver was possibly the 
starting point of the observed inductions (30). 
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Table 4.1 Liver weight and fatty acid content for male mice fed trans-10, cis-12-CLA (24) 
 
 Dietary trans-10, cis-12-CLA 
0% 0.30% SEM P < 
*
 
Liver weight (g) 1.99 2.36 0.12 0.04 
Adipose weight (g) 0.61 0.18 0.05 0.0001 
Total fatty acids (Íg/mg) 38.8 59.0 3.0 0.01 
*
 Probability of a linear effect due to dietary trans-10, cis-12-CLA content. 
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Table 4.2 Summary of mouse studies including liver weight, liver TG, adipose tissue 
measurements in response to trans-10, cis-12-CLA 
 
 trans-10, cis-12-CLA* 
Reference Dose Duration Liver  
weight 
Liver  
TG 
Adipose 
tissue 
Clément et al. 
(2002) (33) 
0.4% 
(w/w) 
4 wks 3.1-fold ↑  85% ↓ 
Degrace et al. 
(2003) (30) 
10 g 4 wks 60% ↑ 655% ↑ 83% ↓ 
Warren et al. 
(2003) (113) 
0.5% 8 wks 98% ↑ 472% ↑ 59% ↓ 
Degrace et al. 
(2004) (31) 
1% 4 wks 80% ↑ 646% ↑ 85% ↓ 
Kelley et al. 
(2004) (25) 
0.5% 8 wks  30% ↑  
House et al. 
(2005) (248) 
1% 2 wks 33% ↑ 61% ↑ (fat) 58% ↓ 
Viswanadha et al. 
(2006) (24) 
0.30% 6 wks 17% ↑ 52% ↑ (total 
fatty acids) 
81% ↓ 
Halade et al. 
(2009) (48) 
0.5% 0.5 y 50% ↑  73% ↓ 
Ashwell et al. 
(2010) (32) 
1% 2 wks 33% ↑ 62.5% ↑ (fat)  
* The increase or decrease in percentage was calculated by (CLA – Control) / Control. 
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Table 4.3 Hepatic expression of genes related to lipogenesis and carbohydrate metabolism 
following trans -10, cis -12-CLA consumption by growing male mice 
 
 Treatments
1 
 Time  
Gene Control CLA  Week 2 Week 6 SEM
2 
Carbohydrate Metabolism       
Gck -0.45 -0.49  -0.31 -0.63 0.28 
Pc -0.31
 
 -0.08
 
  -0.08
 
 -0.32
 
 0.28 
Pck1 -1.74
 a
 -0.29
b
  -0.80 -1.24 0.62 
Slc2a1 -0.07
 
 0.21
 
  0.18 -0.04 0.14 
       
Liver TG Synthesis & 
Transport 
      
Apob -0.33 -0.05  -0.09 -0.29 0.19 
Cideb -1.13
 a
 -0.04
 b
  -0.35 -0.81 0.50 
Dgat1 -0.02 0.30  0.23 0.049 0.17 
Dgat2 0.03 0.25  0.26 0.02 0.15 
Gpam -0.31
 a
 0.44
 b
  0.13 0.004 0.17 
Mttp -0.37
 a
 0.14
 b
  0.002 -0.22 0.17 
Plin2 -0.43
 a
 0.40
 b
  -0.01 -0.02 0.18 
Scd -0.92
 a
 0.05
 b
  -0.50 -0.37 0.19 
       
De novo Fatty Acid 
Synthesis 
      
Acaca 0.22
 a
 0.72
 b
  0.42 0.51 0.11 
       
Lipolysis       
Lipc -0.95 -0.20  -0.15 -0.10 0.54 
Pnpla2 -0.04 0.14  0.24 -0.13 0.24 
 
Transcription Regualtion 
      
Chrebp -0.22 -0.17  -0.19 -0.19 0.08 
Srebf1 -0.22
 a
 0.14
 b
  0.04 -0.11 0.11 
1
Means with different superscripts differ (P  0.05). 
2
SEM = the largest standard error of the mean is shown.
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Table 4.4 Hepatic expression of genes related to lipid catabolism following trans -10, cis 
-12-CLA consumption by growing male mice 
 
 Treatments
1 
 Time  
Gene Control CLA  Week 2 Week 6 SEM
2 
Fatty Acid Oxidation 
& Energy Metabolism 
      
Aacs -0.21 -0.29  -0.26 -0.25 0.31 
Acox1 -0.22
 a
 0.13
 b
  -0.08 -0.0032 0.14 
Bdh1 -0.20
 a
 0.13
 b
  0.06 -0.12 0.12 
Cpt1a -0.43 -0.32  -0.36 -0.39 0.14 
Insig1 -0.79
 
 0.35
 
  -0.23 -0.20 0.45 
Mlycd 0.00054 -0.17  -.0.07 -0.11 0.10 
Pdk4 -1.85
 a
 0.47
 b
  -0.81 -0.57 0.50 
Ucp2 -0.31
 a
 0.15
 b
  -0.04 -0.11 0.10 
 
Ketogenesis 
      
Hmgcs2 -0.16
a 
0.13
b 
 0.10
a 
-0.13
b 
0.10 
       
Fatty Acid Uptake       
Cd36 -1.50
 a
 1.11
 b
  -0.01 -0.35 0.55 
Slc27a2 -0.23 -0.04  -0.07 -0.20 0.18 
 
Transcription 
Regulation 
      
Pparα -0.33 -0.19  -0.23 -0.30 0.12 
1
Means with different superscripts differ (P  0.05). 
2
SEM = the largest standard error of the mean is shown.
77 
 
Table 4.5 Hepatic expression of genes related to stress following trans -10, cis -12-CLA 
consumption by growing male mice 
 
1
Means with different superscripts differ (P  0.05). 
2
SEM = the largest standard error of the mean is shown. 
 Treatments
1
  Time  
Gene Control CLA  Week 2 Week 6 SEM
2 
Inflammation       
Saa1 -0.50 -0.21  -0.17 -0.54 0.31 
       
Stress Response       
Angptl3 -0.54 0.07  -0.26 -0.21 0.42 
Angptl4 0.01 -0.29  -0.53 0.25 0.35 
Atf6 -0.27 0.17  0.16 -0.26 0.46 
Ddit3 -0.25
 
 0.37
 
  -0.11 0.24 0.30 
Eif2ak3 -0.55 -0.10  -0.32 -0.32 0.46 
Fgfr2 -0.09 0.19  -0.58 0.68 0.49 
Hspa1b -1.04 -0.54  -0.91 -0.67 0.62 
Xbp1 -1.15 -0.55  -0.46 -1.23 0.63 
78 
 
Table 4.6 Summary of various hepatic measurements in response to trans-10, cis-12-CLA 
 
Reference Subject Dosage* 
Liver 
Wt TG Protein FFA 
VLDL 
secretion 
Ketone body 
production 
BHBA/
AA 
TG 
secretion 
Degrace et al. 
(2003) (30) 
Mice 10 g 60%↑ 655% ↑   2-fold↑    
Kelley et al. 
(2004) (25) 
Mice 0.5%  432%↑  ↑     
Degrace et al. 
(2004) (31) 
Mice 1% 80%↑ 646%↑ 19%↓ 44%↓     
Sakono et al. 
(1999) (236) 
Rat 1% CLA 
Mix 
━ ━    ↑ ↑  
Lin et al.  
(2001) (249) 
HepG2 cell 1 mmol/l  4-fold↑      ↓ 
* Without special indication (e.g. CLA Mix), dosage means the amount of trans-10, cis-12-CLA used. 
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Table 4.7 Summary of various serum measurements in response to trans-10, cis-12-CLA 
 
Reference Subject Dosage* 
Serum 
Glucose Insulin 
Insulin 
resistance 
CHL TG ApoB NEFA 
Clément et al. 
(2002) (33) 
Mice 0.4%  
(w/w) 
━ 10-fold↑      
Halade et al. 
(2009) (48) 
Mice 0.5% 31%↑ 51%↑   20%↓  19%↑ 
Degrace et al. 
(2003) (30) 
Mice 10 g     67%↓ 53%↓  
Degrace et al. 
(2004) (31) 
Mice 1%     64%↓  44%↓ 
Peters et al.  
(2001) (125) 
Mice 0.5% CLA 
Mix 
━   ━ 49%↓   
Tsuboyama-Kasaoka et al.  
(2000) (22) 
Mice 1%  
(w/w) 
━ ↑ ↑     
* Without special indication (e.g. CLA Mix), dosage means the amount of trans-10, cis-12-CLA used. 
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Figure 4.1 Currently known relationships among genes analyzed based on manually curated examination of the published literature within the 
Ingenuity Pathway Analysis (www.igenuity.com) knowledge base. Genes are grouped by the predominant process they play in lipid metabolism. 
Different shapes denote the type of protein encoded by the specific genes, including enzymes, ligand-dependent nuclear receptors, transcription 
regulators, and transporters. Letters along the edges denote effects on activity (A), expression (E), localization (LO), proteolysis (L), RNA 
binding (RB), protein-DNA binding (PD), and protein-protein binding (PP). Gene names are as in Table 1.1. 
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Figure 4.2 Interrelationships among cellular pathways regulating lipid and carbohydrate metabolism in the mouse liver.
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CHAPTER 5 
Conclusions 
All in all, our study found that the hepatic steatotic effect of trans-10, cis-12-CLA 
might be due to increased fatty acid uptake, stimulated TG synthesis, enhanced storage 
capacity of lipid droplets as well as insufficiently induced VLDL assembly/secretion 
mechanism in the liver. Impaired β-oxidation would not be a factor contributing to hepatic 
steatosis induced by trans-10, cis-12-CLA. Our results provide new evidences to advance in 
the knowledge of the effect of this supplement on hepatic gene expression in a model of 
growing male mice. Furthermore, since the growing male mice was fed relatively low amount 
of trans-10, cis-12-CLA for 6 weeks, it seems to be a more reasonable model to speculate  
trans-10, cis-12-CLA’s long-term effect on hepatic steatosis in humans. However, we did not 
capture the entire picture of the molecular mechanisms, since we did not measure gene 
product activity. 
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APPENDIX A 
Supplementary Tables 
 
Table A.1 qPCR performance among the thirty-eight genes measured in liver. 
 
Gene Median Ct
1
 Median ∆Ct2 Slope3 (R2)4 Efficiency5 
Aacs 24.6  3.0  -3.91  0.991  1.80  
Acaca 24.4  2.8  -3.39  0.997  1.97  
Acox1 20.6  -1.1  -3.54  0.996  1.92  
Angptl3 22.7  1.0  -2.78  0.988  2.29  
Angptl4 28.5  6.8  -3.82  0.948  1.83  
Apob 19.9  -1.7  -4.01  0.976  1.78  
Atf6 26.3  4.6  -2.07  0.971  3.05  
Bdh1 21.7  0.0  -3.58  0.997  1.90  
Cd36 26.5  4.9  -1.27  0.906  6.15  
Chrebp 21.9  0.3  -3.72  0.995  1.86  
Cideb 21.6  0.0  -2.95  0.999  2.18  
Cpt1a 23.0  1.3  -5.37  0.971  1.54  
Ddit3 26.6  5.0  -2.80  0.992  2.28  
Dgat1 25.7  3.9  -2.93  0.992  2.19  
Dgat2 21.1  -0.5  -3.20  0.993  2.05  
Eif2ak3 26.2  4.5  -2.13  0.981  2.94  
Fgfr2 26.7  5.2  -2.86  0.974  2.24  
Gck 24.1  2.5  -4.03  0.990  1.77  
Gpam 21.7  0.1  -3.63  0.997  1.89  
Hngcs2 19.5  -2.1  -3.47  0.998  1.94  
Hspa1b 25.6  3.9  -2.62  0.980  2.41  
Insig1 21.4  -0.2  -2.55  0.997  2.47  
Lipc 21.5  -0.2  -2.26  0.981  2.77  
Mlycd 24.5  2.8  -3.44  0.998  1.95  
Mttp 23.2  1.5  -3.46  0.999  1.95  
Pc 23.1  1.4  -3.87  0.995  1.81  
Pck1 20.0  -1.8  -2.86  0.999  2.24  
Pdk4 26.2  4.5  -3.20  0.991  2.05  
Plin2 22.7  1.1  -3.39  0.996  1.97  
Pnpla2 25.1  3.2  -3.20  0.994  2.05  
Ppara 23.3  1.6  -3.84  0.996  1.82  
 
 
 
100 
 
Table A.1 (cont.) 
 
Gene Median Ct
1
 Median ∆Ct2 Slope3 (R2)4 Efficiency5 
Saa1 23.9  2.2  -2.79  0.997  2.28  
Scd 22.0  0.4  -3.36  0.963  1.99  
Slc27a2 21.5  -0.1  -3.99  0.997  1.78  
Slc2a1 27.3  5.6  -3.33  0.987  2.00  
Srebf1 23.9  2.2  -3.23  0.997  2.04  
Ucp2 25.8  4.1  -3.27  0.993  2.02  
Xbp1 21.0  -0.7  -1.57  0.959  4.34  
1 
The median is calculated considering all time points and all steers. 
2
 The median of ∆Ct is calculated as [Ct gene – geometrical mean of Ct internal controls] for 
each time point and each steer. 
3
 Slope of the standard curve. 
4
 R2 stands for the coefficient of determination of the standard curve. 
5 
Efficiency is calculated as [10(-1 / Slope)]. 
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Table A.2 Accession number, sequence, amplicon size, reference and PCR efficiency of primers use to analyze gene expression by qPCR. 
 
Accession # Gene Primer Primers (5’-3’) Amplicon Size (bp) Source 
NM_030210.1 
 
Aacs F.230 
R.329 
TGGCGCTTGGGAATTACAAT 
CGTGAGTAGACGATTCCACTGAA 
100 In this article 
NM_133360.2 Acaca F.2003 
R.2087 
CCTTCCTGCTCACACACTTCTG 
CTGCCGAGTCACCTTAAGTACATATT 
85  
NM_015729 Acox1 F.436 
R.537 
GCCGTCGAGAAATCGAGAACT 
TCTTAACAGCCACCTCGTAACG 
102  
NM_013913.3 Angptl3  AGGGCTTTGGAGGAGCAGCTAACC 
GCAGTCGGCAGGAAGGTCATCTTG 
 (250) 
NM_020581.1 Angptl4  TTCCAACGCCACCCACTTACA 
ACCAAACCACCAGCCACCAGA 
 (251) 
NM_009693.2 
 
Apob  ATCTGACTGGGAGAGACAAGTAG 
CGATCAATAATCTCAGCAATAGTTC 
 (252) 
NM_001081304.1 Atf6  TGCTAGGACTGGAGGCCAGGCTCAA 
CATGTCTATGAACCCAGCCTCGAAGT 
 (253) 
NM_175177.3 
 
Bdh1 F.402 
R.201 
GTCAGGCAGATGCGGCTAGT 
AGGAAGCCTTTTGAGTGCAGAT 
100 In this article 
NM_007643.3 Cd36 F.726 
R.846 
GAGGTCCTTACACATACAGAGTTCGTT 
ACAGACAGTGAAGGCTCAAAGATG 
121 In this article 
NM_021455.3 Chrebp F.733 
R.847 
GCTTCTAGACCTGGACTGCTTCTT 
AGCATTGCCAACATAAGCATCTT 
115  
NM_009894.2 Cideb  CCCCAAGAGTGGGATGTTGT 
GGGATTTTGCTTGTACACATCGA 
100 In this article 
NM_013495.1 Cpt1a F.1722 
R.1838 
CCTGCATTCCTTCCCATTTG 
TTGCCCATGTCCTTGTAATGTG 
117  
NM_007837.2 
 
Ddit3  GCAAGGAAGAACTAGGAAACGGA 
CAATGTACCGTCTATGTGCAAGC 
 (254) 
NM_010046.2 
 
Dgat1 F.804 
R.923 
ACAACCTGACCTACCGAGATCTCT 
TCTCAAGAACTCGTCGTAGCAGAA 
120 In this article 
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Table A.2 (cont.) 
 
Accession # Gene Primer Primers (5’-3’) Amplicon Size (bp) Source 
NM_026384.3 
 
Dgat2 F.551 
R.656 
CCAAGAAAGGTGGCAGGAGAT 
GTCAGCAGGTTGTGTGTCTTCAC 
106 In this article 
NM_010121.2 Eif2ak3  AACGGAAGGAGTCTGAAACTCAGT 
TTGGCTCAAAATCTGTTAGGTATCG 
 (255) 
NM_201601.2 Fgfr2  AAGGTTTACAGCGATGCCCA 
ACCACCATGCAGGCGATTAA 
 (256) 
NM_010292.4 
 
Gck F.389 
R.489 
TCTCTGACTTCCTGGACAAGCA 
GATGCCCTTGTCTATGTCTTCGT 
101 In this article 
NM_008149.3 
 
Gpam F.725 
R.824 
TGGGTGTTACTAAAGCTCTTCAACA 
GCGGCAGGTTCGTCTCAGT 
100 In this article 
NM_008256.3 Hmgcs2 F.515 
R.621 
CACTGACATCGAGGGCATAGATAC 
CATAGCGACCATCCCAGTAGCT 
107 In this article 
NM_010478.2 
 
Hspa1b  AATTTAACAGTCAACGCAATTACC 
AACAGACTCTTTGCACTTGATAGC 
 (257) 
NM_153526.3 Insig1  AGGACGACAGTTAGCTATGGGTG 
CCCCCTTACCCGACTCTCACATAC 
 (258) 
NM_008280.2 
 
Lipc F.722 
R.831 
TTCTCGGAGCAAAGTTCACCTAA 
CCAGCCCTGTGATTCTTCCA 
110 In this article 
NM_019966.2 
 
Mlycd F.903 
R.1007 
CGCTGCCATCTTCTACTCCAT 
AATTCCTTCTGCAGCTCCTTGA 
105 In this article 
NM_008642.1 
 
Mttp F.234 
R.334 
GACAGCGTGGGCTACAAAATC 
GCTGTTATCGTGACTTGGATCACTT 
101 In this article 
NM_008797.2 
 
Pc F.686 
R.799 
CGCATGAGTTCTCCAACACCTA 
TGTAATTCTCTTCCAACTCCTCATAGC 
114 In this article 
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Table A.2 (cont.) 
 
Accession # Gene Primer Primers (5’-3’) Amplicon Size (bp) Source 
NM_011044.2 
 
Pck1 F.1453 
R.1576 
CTGAAGGTGTCCCCCTTGTC 
GGGTCGTGCATGATGATCTTG 
124 In this article 
NM_013743.2 
 
Pdk4  CACATGCTCTTCGAACTCTTCAAG 
TGATTGTAAGGTCTTCTTTTCCCAAG 
 (259) 
NM_007408.3 
 
Plin2 F.725 
R.825 
AGCTGGAGATGGAAGCAAAAAA 
CCGAGAGCAGAGCTTGGTAGA 
101 In this article 
NM_025802.2 
 
Pnpla2 F.875 
R.995 
TGGAACCAAAGGACCTGATGAC 
AACAAGCGGATGGTGAAGGA 
121 In this article 
NM_011144.3 Ppara  ACTTCGCTATCCAGGCAGAA 
CAGACCAACCAAGTGTTGTGA 
117  
NM_009117.3 
 
Saa1  GAAGGAAGCTAACTGGAAAAACTC 
CAGGCCCCCAGCACAACCTACT 
 (260) 
NM_009127.3 Scd  TCCAGTGAGGTGGTGTGAAA 
TTATCTCTGGGGTGGGTTTG 
  
NM_011978.2 
 
Slc27a2 F.1095 
R.1194 
ACACCGCAGAAACCAAATGAC 
CCCCAAATCTCTTGATGAACTCTCT 
100 In this article 
NM_011400.2 
 
Slc2a1 F.318 
R.419 
CCAGAAGGTTATTGAGGAGTTCTACAA 
GCCACGGAGAGAGACCAAAG 
102 In this article 
NM_011480.2 Srebf1  GTGAGCCTGACAAGCAATCA 
GGTGCCTACAGAGCAAGAGG 
  
NM_011671 Ucp2 F.881 
R.983 
GGCCTCTGGAAAGGGACTTC 
TGGCTTTCAGGAGAGTATCTTTGA 
103  
NM_013842.2 Xbp1  TCCGCAGCACTCAGACTATGT 
ATGCCCAAAAGGATATCAGACTC 
 (261) 
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Table A.3 Sequencing results of PCR products from primers of genes designed for this experiment. Best hits using BLASTN 
(http://www.ncbi.nlm.nih.gov) are shown. Similar information for remaining genes was reported previously. 
 
Gene Sequence 
Aacs GGACTTTTGGGCTGAGTTCTGGAAGTTCAGTGGAATCGTCTACTCACG 
Acaca GTACATATCTTAGTAAGGAATCAAATATGTACTTAAGGTGACTCGGCAGA 
Acox1 
 
Angptl3 CTCAGGAGCACCCAGAAGTAACATCACTCAAAAGTTTTGTAGAACAGCAAGACAACAGCATAAGAGAACTCCT
CCAGAGTGTGGAAGAACAGTATAAACAATTAAGTCAACAGCACATGCAGATAAAAGAAATAGAAAAGCAGCTC
AGAAAGACTGGTATTCAAGAACCCTCAGAAAATTCTCTTTCTTCTAAATCAAGAGCACCAAGAACTACTCCCCCT
CTTCAACTGAACGAAACAGAAAATACAGAACAAGATGACCTTCCTGCCGACTGC 
Angptl4 GGGAGCGGCACAGTGGACTTTTCCAGATCCAGCCTCTGGGGTCTCCACCATTTTTGGTCAACTGTGAGATGACTT
CAGATGGAGGCTGGACAGTGATTCAGAGACGCCTGAACGGCTCTGTGGACTTCAACCAGTCCTGGGAAGCCTAC
AAGGATGGCTTCGGAGATCCCCAAGGCGAGTTCTGGCTGGGCCTGGAAAAGATGCACAGCATCACAGGGAACC
GAGGAAGCCAATTGGCTGTGCAGCTCCAGGACTGGGATGGCANTGCCNAATTGCTCCAATTTCCCATCCATTTG
GGGGGTGAGGA 
Apob AAATTATAGAATTACAGATAATGATGTACTAATTGCCATAGATAGTGCCAAAATCAACTTCAATGAAAAACTCT
CTCAACTTGAGACATACGCGATATAATTTGATCAGTATATTAAAGATAATTATGATCCACATGACTTAAAAAGA
ACTATTGCTGAGATTATTGATCGAA 
Atf6 AGGAGAATGGCTCCCTGAAGCGACAGCTGGACGAGGTGGTGTCAGAGAACCAGAGGCTCAAAGTCCCAAGTCC
AAAGCGAAGAGCTGTCTGTGTGATGATAGTATTAGCATTTATAATGCTGAACTATGGGCCCATGAGCATGCTGG
AGCAAGAATCCCGAAGAGTGAAACCTAGTGTGAGCCCTGCCAATCAGAGGAGGCATCTCTTGGAATTTTCAGCA
AAAGAAGTTAAAGACACATCAGATGGTGACAACCAGAAAGACAGTTACAGCTATGATCACTCTGTGTCCAATGA
CAAAGCTTTAATGGTGCTAAGTGAAGAGCCATTGCTTTATATGCCTCCACCTCCATGTCAACCCCTGATTAACAC
AACAGAGTCTCTCAGGTTGAACCATGAACTTCGAGGCTGGGTTCATAGACATGA 
Bdh1 GATTTGGGTTCTCACTGGCCAAGCATCTGCACTCAAAAGGCTTCCT 
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Table A.3 (cont.) 
 
Gene Sequence 
Cd36 CCATCTTTGAGCCTTCACTGTCTGT 
Chrebp CTCTTCACCATGACACAGCCCAGTCCTTCGTCCCTGCAGCTGCCCCCAGAAGAATGCTTATGTTGGCAATGCTAA 
Cideb AGCAAGGACATCGCCCGCATCACCTTCGATGTGTACAAGCAAAATCCCC 
Cpt1a CTGATCAGAAGTGCCGGACGAGTCCCGATGCCTTCATCCAGCTGGCACTGCAGCTCGCACATTACAAGGACATGG
GCAAA 
Ddit3 CCGGCCTGGGAGCACGCATGAAGGAGAAGGAGCAGGAGAACGAGCGGAAAGTGGCACAGCTAGCTGAAGAGA
ACGAGCGGCTCAAGCAGGAAATCGAGCGCCTGACCAGGGAGGTGGAGACCACACGGCGGGCTCTGATCGACCG
CATGGTCAGCCTGCACCAAGCATGAACAGTGGGCATCACCTCCTGTCTGTCTCTCCGGAAGTGTACCCAGCACCA
TCGCGCCAGCGCCAAGCATGTGACCCTGCACTGCACTGCACATGCTGAGGAGGGGACTGAGGGTAGACCAGGAG
AGGGCTCGGCTTGCACATAGACGGTACATTG 
Dgat1 TCAACTTTCCTCGGTCCCCCCGAATACGAAAGCGCTTTCTGCTACGACGAGTTCTTGAGA 
Dgat2 GTGTGCGGCTACTTCCGAGACTACTTTCCCATCCAGCTGGTGAAGACACACAACCTGCTGAC 
Eif2ak3 GTGCCGATGTCAGTGACAACAGCTGGAATGACATGAAGTACTCAGGATACGTATCCCGATACCTAACAGATTTTG
AGCCAA 
Fgfr2 ACGGCAGTAAATACGGGCCTGATGGGCTGCCCTACCTCAAGGTCCTGAAGCACTCGGGGATAAATAGCTCCAAT
GCAGAAGTGCTGGCTCTGTTCAATGTGACGGAGATGGATGCTGGGGCAATATATATGTAAGGTCTCCAATTATAT
AGGGCAGGCCAACCAGTCTGCCTGGCTCACTGTCCTGCCCAAACAGCAAGCGCCTGTGAGAGAGAAGGAGATCA
CGGCTTCCCCAGATTATCTGGAGATAGCTATTTACTGCATAGGGGTCTTCTTAATCGCCTGCATGGTG 
Gck CCCCGTGGCTTCACCTTCTCCTTCCCGTTAAGGCACGAAGACATAGACAAGGGCATC 
Gpam AGGGTCAACTCGAGATGGTCAAGGCTGCAACTGAGACGAACCTGCCGC 
Hmgcs2 GCGGCACAGCCTCCCTCTTCAATGCTGCCAACTGGATGGAGTCCAGCTACTGGGATGGTCGCTATG 
Hspa1b CCATGAAGAAGACTTTAAATAACCTTGACAGTAATCGGTGCCCAAGCAGCTATCAAGTGCAAAGAGTCTGTT 
 
106 
 
Table A.3 (cont.) 
 
Gene Sequence 
Insig1 CACATGGTTCAGAGTGGAAGCAGGATGTAGAGACACTGGTCCTGGGTGTGATGAAGATGATCTTTTTCTCAATG
TTCCATTTAGGCTGGGCTGACGATAAATGACTCCTAAAGACATGTTCACTTAGTCTAGACTAGCAAATGGAGGC
AAGGACTGCTTACCTAAAAGTCTTACCTTGCTCCCCCACCCTCACACCTGTCTTCTTTGGAACATTCCATCCCAG
GCTGTATGTGAGAGTCGGGGTAAGGGGG 
Lipc CGTCTCAGGGTTCGCAGGCAGCTCCATGGACGGGAAGAACAAGATTGGAAGAATCACAGGGC 
Mlycd GAGCTCGGGACCTTCCTCATAAAGAGAGTGGTCAAGGAGCTGCAGAAGGAATT 
Mttp GGAGGAATCCTGATGGTGATGATGATCAAGTGATCCAAGTCACGATAACAGC 
Pc GCCGCCTACGGAGGTGGGGGCCGCGGCATGCGGGTCGTGCATAGCTATGAGGAGTTGGAAGAGAATTACA 
Pck1 GGAGCAGCCATGAGATCTGAGGCCACAGCTGCTGCAGAACACAAGGGCAAGATCATCATGCACGACCC 
Pdk4 GAGCATCAAGAAAACCGTCCTTCCTTGACCCCAGTAGAGGCCACTGTCGTCTTGGGAAAAGAAGACCTTACAAT
CAA 
Plin2 AAGCCGAGCAACTATGAACGGCTGGAGTCCCTGTCTACCAAGCTCTGCTCTCGGG 
Pnpla2 GCGCCTGGCAACGGCCATGATGGTGCCCTATACTCTGCCGCTGGAGAGTGCAGTGTCCTTCACCATCCGCTTGTT  
Ppara 
 
Saa1 ATGCTGCTCAAAGGGGTCCCGGGGGAGTCTGGGCTGCTGAGAAAATCAGTGATGGAAGAGAGGCCTTTCAGGA
ATTCTTCGGCAGAGGACATGAGGACACCATTGCTGACCAGGAAGCCAACAGACATGGCCGCAGTGGCAAAGAC
CCCAATTACTACAGACCTCCTGGACTGCCTGACAAATACTGAGCGTCCTCCTATTAGCTCAGTAGGTTGTGCTGG
GGGCCTGA 
Scd CTCAGCCAAGGTGCCTCTTAGCCACTGAATTGCTATGTTATCCTTTCTCTTGTAACAAACCCACCCCAGAGATAA
A 
Slc27a2 GGAAATGGCTTACGAGGAGATGTGTGGAGAGAGTTCATCAAGAGATTTGGGG 
Slc2a1 GGAGAGCCCATCCCATCCACCACACTCACCACGCTTTGGTCTCTCTCCGTGGC 
Srebf1 GGTCAAGAATCTGGAAATTGCAGAGGCTGCACTGGCCCGATGGCACCCTCTTGCTCTGTAGGCACCAAT 
Ucp2 
 
Xbp1 TCCCCAGAACATCTTCCCATGGACTCTGACACTGTTGCCTCTTCAGATTCTGAGTCTGATATCCTTTTGGGCAT  
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Table A.4 Sequencing results of genes using BLASTN from NCBI against nucleotide collection (nr / nt) with total score. 
 
Gene Best hit in NCBI Score 
Aacs Mus musculus acetoacetyl-CoA synthetase (Aacs), mRNA 80.1 
Acaca Mus musculus acetyl-Coenzyme A carboxylase alpha (Acaca), mRNA 89.1 
Acox1 Mus musculus acyl-Coenzyme A oxidase 1, palmitoyl (Acox1), mRNA. 80.1 
Angptl3 Mus musculus angiopoietin-like 3 (Angptl3), mRNA 89.1 
Angptl4 Mus musculus angiopoietin-like 4 (Angptl4), mRNA 78.3 
Apob Mus musculus chromosome 12 genomic contig, strain C57BL/6J 89.1 
Atf6 Mus musculus activating transcription factor 6 (Atf6), mRNA 94.5 
Bdh1 Mus musculus 3-hydroxybutyrate dehydrogenase, type 1 (Bdh1),mRNA 78.3 
Cd36 Mus musculus CD36 antigen (Cd36), mRNA 94.5 
Chrebp Mus musculus MLX interacting protein-like (Mlxipl), Mrna 87.3 
Cideb Mus musculus cell death-inducing DNA fragmentation factor, alpha subunit-like effector B (Cideb), mRNA 80.1 
Cpt1a Mus musculus carnitine palmitoyltransferase 1a, liver (Cpt1a), 78.3 
Ddit3 Mus musculus DNA-damage inducible transcript 3 (Ddit3), mRNA 85.5 
Dgat1 Mus musculus diacylglycerol O-acyltransferase 1 (Dgat1), mRNA 89.1 
Dgat2 Mus musculus diacylglycerol O-acyltransferase 2 (Dgat2), mRNA 81.9 
Eif2ak3 Mus musculus eukaryotic translation initiation factor 2 alpha kinase 3 (Eif2ak3), mRNA 81.9 
Fgfr2 Mus musculus fibroblast growth factor receptor 2 (Fgfr2), transcript variant 2, mRNA 74.7 
Gck Mus musculus glucokinase (Gck), mRNA 83.7 
Gpam Mus musculus glycerol-3-phosphate acyltransferase, mitochondrial (Gpam), mRNA 81.9 
Hmgcs2 Mus musculus 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (Hmgcs2), mRNA 85.5 
Hspa1b Mus musculus heat shock protein 1B (Hspa1b), mRNA 89.1 
Insig1 Mus musculus insulin induced gene 1 (Insig1), mRNA 87.3 
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Table A.4 (cont.) 
 
Gene Best hit in NCBI Score 
Lipc Mus musculus lipase, hepatic (Lipc), mRNA 80.1 
Mlycd Mus musculus malonyl-CoA decarboxylase (Mlycd), mRNA 80.1 
Mttp Mus musculus microsomal triglyceride transfer protein (Mttp), mRNA 83.7 
Pc Mus musculus pyruvate carboxylase (Pcx), mRNA 89.1 
Pck1 Mus musculus phosphoenolpyruvate carboxykinase 1, cytosolic (Pck1), mRNA 76.5 
Pdk4 Mus musculus pyruvate dehydrogenase kinase, isoenzyme 4 (Pdk4), mRNA 92.7 
Plin2 Mus musculus adipose differentiation related protein (Adfp), mRNA 80.1 
Pnpla2 Mus musculus patatin-like phospholipase domain containing 2 (Pnpla2) mRNA 78.3 
Ppara Mus musculus peroxisome proliferator activated receptor alpha (Ppara) 76.5 
Saa1 Mus musculus serum amyloid A 1 (Saa1), mRNA 85.5 
Scd Mus musculus stearoyl-Coenzyme A desaturase 1 (Scd1), mRNA 74.7 
Slc27a2 Mus musculus solute carrier family 27 (fatty acid transporter), member 2 (Slc27a2), mRNA 85.5 
Slc2a1 Mus musculus solute carrier family 2 (facilitated glucose transporter),member 1 (Slc2a1), mRNA 87.3 
Srebf1 Mus musculus sterol regulatory element binding factor 1 (Srebf1), mRNA 74.7 
Ucp2 Mus musculus uncoupling protein 2 (mitochondrial, proton carrier) 81.7 
Xbp1 Mus musculus X-box binding protein 1 (Xbp1), mRNA 81.9 
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Table A.5 In vitro studies of the trans-10, cis-12-CLA included in the literature review. 
 
Reference Subjects Dose Duration Results 
Bretillon et al. 
(1999) (111) 
Rat liver 
microsomes 
20 to 120 
nmol/L 
15 min 
Trans-10, cis-12-CLA significantly inhibited the conversion of stearic aicd and 
the Δ6 desaturation of linoleic acid at the highest inhibitor/substrate ratio. 
Yotsumotoet et al. 
(1999) (146) 
HepG2 cells 10 μmol/L 24 hrs 
Trans-10, cis-12-CLA inhibited cellular triglyceride synthesis and reduced 
apoB secretion. 
Lin et al. 
(2001) (144) 
HepG2 cells 1 mmol/L 5 hrs 
Trans-10, cis-12-CLA suppressed TG secretion in spite of the fact that it 
increased 4-fold the cellular TG content. 
Choi et al. 
(2001) (109) 
HepG2 cells 45 μmol/L 48 hrs 
Human SCD activity was ↓ by the trans-10, cis-12-CLA directly, without 
changes in SCD gene expression, suggesting that this isomer regulates human 
SCD activity mainly by a posttranslational mechanism. 
Clément et al. 
(2002) (33) 
COS-1 cells 
10 to 200 
μmol/L 
36 hrs 
Trans-10, cis-12-CLA and cis-9, trans-11-CLA were equally efficient at 
activating PPARα, β/σ and γ and inhibiting liver-X-receptor. Thus, the specific 
effect of Trans-10, cis-12-CLA is unlikely to result from direct interaction with 
these nuclear receptors. 
Eder et al. 
(2002) (108) 
HepG2 cells 
1 to 100 
μmol/L 
0.5 or 24 
hrs 
Cells had a markedly lower ratio of MUFA to SFA in lipids than control cells, 
suggesting that trans-10, cis-12-CLA suppresses Δ9-, Δ6- and Δ5-desaturation 
and has significant effects on the metabolism of essential fatty acids in HepG2 
cells. 
Yamasaki et al. 
(2005) (50) 
Rat 
hepatoma 
cells 
0 to 10 
μmol/L 
72 hrs 
1 μmol/L Trans-10, cis-12-CLA demonstrated significant cytotoxic effects on 
rat hepatoma cells. It also induced mitochondria-related apoptosis 
accompanied by lysosomal destabilization in rat hepatoma cells. 
Wei et al. 
(2007) (262) 
Rat 
hepatoma 
cells 
80 μmol/L 
3, 6 or 16 
hrs 
Trans-10, cis-12-CLA reduced SCD1 activity and increased the SFA 
composition of total lipids following incubations with palmitate. 
Co-supplementation of palmitate with Trans-10, cis-12-CLA resulted in a 
significant increase ER stress response genes and apoptosis. 
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Table A.6 In vivo studies of the trans-10, cis-12-CLA included in the literature review. 
 
Reference Subjects Dose Duration Results 
de Deckere et al. 
(1999) (85) 
Male F1B 
hybrid hamsters 
6.6 g/kg 
diet 
8 wks 
Trans-10, cis-12-CLA and the CLA mix decreased fasting values of LDL- and 
HDL-cholesterol, increased VLDL-TG and decreased epididymal fat pad 
weights. Trans-10, cis-12-CLA increased liver weight but not liver lipids. Liver 
histology revealed that increased weight was due to hypertrophy. Data suggested 
that Trans-10, cis-12-CLA stimulated the oxidation of all C18 PUFAs. 
Clément et al. 
(2002) (33) 
Female 
C57B1/6J mice 
0.4% 
(w/w) 
4 wks 
Trans-10, cis-12-CLA reduced adipose tissue and triggered a massive 
enlargement of the liver (3.1 fold increase), which displayed the typical features 
of a fatty liver: pale color and accumulation of intracellular lipids. Trans-10, 
cis-12-CLA-induced hyperinsulinemia may trigger liver steatosis by inducing 
both fatty acid uptake and lipogenesis. 
Degrace et al. 
(2003) (30) 
7-wk-old male 
C57BL/6j mice 
10 g 4 wks 
This study demonstrated that the steatosis accompanying the fat loss induced by 
Trans-10, cis-12-CLA. The 3-fold decrease in plasma TG contents and the 
induction of mRNA expression of LDL receptors concomitantly observed in 
Trans-10, cis-12-CLA-fed mice suggested an increase in the lipoprotein 
clearance at the level of the liver itself. 
Warren et al. 
(2003) (113) 
8-wk-old 
female mice 
0.5% 8 wks 
Body and retroperitoneal adipose tissue weights were significantly lower and 
liver weights were significantly greater (100%) in the Trans-10, cis-12-CLA 
group. Livers from animals in the Trans-10, cis-12-CLA group contained 5 
times more lipids than in the control group. Trans-10, cis-12-CLA decreased 
PPARα mRNA, suggesting that PPARα did not mediate the effects of Trans-10, 
cis-12-CLA on body composition. 
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Table A.6 (cont.) 
 
Reference Subjects Dose Duration Results 
Kelley et al. 
(2004) (25) 
8-wk-old femal 
C57BL/6N mice 
0.5% 8 wks 
Livers from animals fed Trans-10, cis-12-CLA diet contained 4 times more 
lipids than those of the control group; this was mainly due to an increase in the 
TG fractions. Trans-10, cis-12-CLA caused an increase in the weight 
percentage of 18:1n-9, possibly due to an increased activity of SCD. 
Zabala et al. 
(2004) (114) 
9-wk-old male 
hamsters 
5 g 6 wks 
Trans-10, cis-12-CLA produced significantly greater liver weight, but also 
significantly decreased liver fat accumulation. No changes in mRNA levels of 
Srebp-1a, Srebp-1c and lipogenic enzymes, or in the activities of these 
enzymes, were observed. 
Sanders et al. 
(2004) (89) 
Growing female 
obese Zucker rats 
1.5 g/kg 
BW 
3 wks 
Average daily gain was reduced 44% by the Trans-10, cis-12-CLA. Trans-10, 
cis-12-CLA increased liver lipid content by 33% without effects on liver 
weight. 
Degrace et al. 
(2004) (31) 
7-wk-old male 
C57BL/6J mice 
1% 4 wks 
Mice fed the Trans-10, cis-12-CLA-fed had enlarged livers and hypotrophied 
periepididymal adipose tissues. CPT1 and carnitine-dependent palmitate 
oxidation activities were also significantly greater in Trans-10, cis-12-CLA-fed 
mice than in the two other groups, indicating that FA oxidation capacities were 
increased in mice fed Trans-10, cis-12-CLA. 
House et al. 
(2005) (248) 
Adult male mice 1% 2 wks 
Trans-10, cis-12-CLA reduced weights of adipose tissues and increased liver 
weight by 34%. 
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Table A.6 (cont.) 
 
Reference Subjects Dose Duration Results 
Viswanadha et al. 
(2006) (24) 
4-wk-old CD-1 
mice 
0.15% or 
0.30% 
6 wks 
Liver weight of male and female mice increased in response to Trans-10, 
cis-12-CLA in a dose-dependent manner and the increase was accompanied by 
an increase in total FA content. Unlike adipose tissue, overall hepatic SCD 
mRNA expression was not affected by Trans-10, cis-12-CLA. 
Gudbrandsen et 
al. 
(2009) (36) 
5-wk-old male 
obese Zucker 
rats 
1% 10 d 
Trans-10, cis-12-CLA reduced the liver TG content without improving the 
overall adiposity, enhanced hepatic mitochondrial and peroxisomal β oxidation 
by stimulation of PPARα. The reduced hepatic TG content may be partly due 
to lower activity of SCD. 
Halade et al. 
(2009) (48) 
11-m-old 
female 
C57B1/6J mice 
0.5% 0.5 y 
Trans-10, cis-12-CLA was found to reduce the fat mass and to increase the 
lean mass but significantly contributed to increase insulin resistance and liver 
hypertrophy. 
Ashwell et al. 
(2010) (32) 
9-wk-old male 
mice 
1% 2 wks 
The mice fed Trans-10, cis-12-CLA had 62.5% more fat in the livers with a 
33% increase in liver weight. 
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Table A.7 Clinical studies of the trans-10, cis-12-CLA included in the literature review. 
 
Reference Subjects Dose Duration Results 
Berven et al. 
(2000) (117) 
55 overweight or 
obese  
> 18 years 
3.4 g/d of CLA 
mixture 
12 wks 
A dose of 3.4 g of CLA daily for 12 weeks is well tolerated in the 
population studied. No clinically significant changes in blood 
parameters or vital signs occurred. The use of CLA does not 
impair liver functions in humans. 
Blankson et al. 
(2000) (45) 
47 overweight or 
obese 
> 18 years 
1.7, 3.4, 5.1 or 6.8 
g/d of CLA 
mixture 
(CLA1:CLA2 = 
1:1) 
12 wks 
CLA may reduce body fat mass (BFM) in humans and no 
addition effect on BFM is achieved with doses > 3.4 g CLA/d. 
Noone et al. 
(2002) (194) 
51 
3 g/d of CLA 
mixture 
(CLA1:CLA2 = 
1:1) 
8 wks 
CLA significantly reduced fasting plasma TG concentrations. No 
significant effect on LDL-cholesterol, HDL-lipid-protein 
composition or reverse cholesterol transport occurred. 
Kamphuis et al. 
(2003) (263) 
54 overweight 
20-50 years 
1.8 or 3.6 g/d of 
CLA mixture 
(CLA1:CLA2 = 
1:1) 
13 wks 
The regain of fat-free mass was favorably, dose-independently 
affected by a 13-week consumption of 1.8 or 3.6 g CLA/day and 
consequently increased the resting metabolic rate. However, it did 
not result in improved body weight maintenance after weight 
loss. 
Malpuech-Brugere 
et al. 
(2004) (102) 
81 overweight 
healthy 
middle-aged 
1.5 or 3 g/d of 
CLA2 
18 wks 
A daily consumption of a drinkable dairy product containing up 
to 3 g of CLA isomers for 18 weeks had no statistically 
significant effect on body composition in overweight, 
middle-aged men and women. 
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Table A.7 (cont.) 
 
Reference Subjects Dose Duration Results 
Whigham et al. 
(2004) (120) 
50 overweight or 
obese 
18-50 years 
6 g/d of CLA 
mixture 
(CLA1:CLA2 ≈ 
1:1) 
1 y 
Body composition did not differ between groups. Laboratory tests 
showed no adverse effects of CLA. The study concluded that 
CLA as Clarinol
TM
 is safe for use in obese humans for at least one 
year. 
Gaullier et al. 
(2005) (264) 
125 
Mean age: 45-48 
3.4 g/d of CLA 
mixture 
(CLA1:CLA2 ≈ 
1:1) 
1 y 
Aspartate amino transferase but not alanine amino transferase, 
increased significantly. Plasma total cholesterol and LDL 
cholesterol were reduced, whereas HDL cholesterol and TGs 
were unchanged. It confirms that CLA decreases BFM in 
overweight humans and may help maintain initial reductions in 
BFM and weight in the long term. 
Iwata et al. 
(2007) (119) 
60 healthy 
overweight 
25-60 years 
3.4 or 6.8 g/d of 
CLA mixture 
(CLA1:CLA2 = 
1:1) 
12 wks 
There was a slight increase in the level of liver enzymes in 6.8 
g/d CLA group at 12 weeks. But these changes were within the 
normal range. The study also indicated that the use of CLA does 
not impair liver function in overweight male humans whose 
blood parameters are within the normal range. 
Wanders et al. 
(2010) (64) 
20 healthy  
BMI < 30 kg/m
2
 
18-60 years 
14.6 g CLA1 +  
4.7 g CLA2 
3 wks 
A daily intake of 19.3 g CLA for 3 weeks does not produce 
clinically relevant effects on markers of liver and kidney function 
in healthy volunteers. 
Venkatramanan et 
al. 
(2010) (116) 
11 moderately 
overweight 
30-60 years 
Milk enriched 
with 1.3 g/d of 
CLA mixture 
24 wks 
Supplementation with CLA-enriched milk did not significantly 
affect liver function or body weight. 
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